Compositions containing antisense oligonucleotides and their use in treating duchenne muscular dystrophy - Patents.com

Antisense oligomers targeting the 53rd exon of the dystrophin gene induce exon skipping, restoring functional dystrophin protein expression and improving muscle function in DMD patients, addressing the lack of effective treatments for the disease.

JP7595719B2Active Publication Date: 2024-12-06NIPPON SHINYAKU CO LTD
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
JP2023143451
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2018-10-01
Filing Date
2023-09-05
Publication Date
2024-12-06
Estimated Expiration
2039-06-26

AI Technical Summary

Technical Problem

Current treatments for Duchenne muscular dystrophy (DMD) are ineffective, and there is a need for therapeutic agents that can restore functional dystrophin protein expression in patients, as the disease is caused by mutations in the dystrophin gene leading to muscle degeneration and weakness.

Method used

The use of antisense oligomers, specifically targeting the 53rd exon of the dystrophin gene, to induce exon skipping and restore the amino acid reading frame, thereby promoting the expression of a functional dystrophin protein through intravenous administration.

Benefits of technology

The treatment significantly increases dystrophin protein expression in skeletal muscle, improves muscle function, and slows the progression of DMD symptoms, as evidenced by improved motor function tests and increased dystrophin levels after 24 weeks of administration.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007595719000038
    Figure 0007595719000038
  • Figure 0007595719000039
    Figure 0007595719000039
  • Figure 0007595719000040
    Figure 0007595719000040
Patent Text Reader

Abstract

To provide compositions comprising antisense oligonucleotides and uses thereof for the treatment of Duchenne muscular dystrophy.SOLUTION: The disclosure provides a pharmaceutical composition for treating Duchenne muscular dystrophy in a human patient, the composition comprising an antisense oligomer comprising a base sequence complementary to a sequence of nucleotides at the positions 36 to 56 from the 5' terminus of exon 53 of human dystrophin gene or a pharmaceutically acceptable salt or hydrate thereof, where the treatment comprises intravenous administration of the antisense oligomer or a pharmaceutically acceptable salt or hydrate thereof to the patient once a week at a dose of 40 mg / kg to 80 mg / kg.SELECTED DRAWING: Figure 2
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to dosage regimens of antisense oligomers that enable skipping of the 53rd exon of the human dystrophin gene, and pharmaceutical compositions containing said oligomers. [Background technology]

[0002] Duchenne muscular dystrophy (DMD) is the most common hereditary progressive muscular atrophy, occurring in approximately 1 in 3,500 male births. In infancy, patients exhibit motor function almost the same as normal humans, but muscle weakness begins to appear from around age 4 to 5. The muscle weakness then progresses, leading to the inability to walk by around age 12, and it is a severe disease that can lead to death from cardiac or respiratory failure in the patient's 20s. Currently, there is no effective treatment for DMD, and there is a strong demand for the development of new therapeutic drugs.

[0003] DMD is known to be caused by a mutation in the dystrophin gene. The dystrophin gene is present on the X chromosome and is a huge gene consisting of 2.2 million base pairs of DNA. The DNA is transcribed into pre-mRNA, which is then spliced ​​to remove introns and synthesize mRNA with 79 exons. This mRNA is translated into 3,685 amino acids to produce the dystrophin protein. The dystrophin protein is involved in maintaining the membrane stability of muscle cells and is necessary to make muscle cells less likely to break down. Because the dystrophin gene in DMD patients has a mutation, functional dystrophin protein is hardly expressed in muscle cells. As a result, the structure of muscle cells cannot be maintained in the bodies of DMD patients, and large amounts of calcium ions flow into the muscle cells. As a result, an inflammation-like reaction occurs, and fibrosis progresses, making it difficult for muscle cells to regenerate.

[0004] Becker muscular dystrophy (BMD) is also caused by a mutation in the dystrophin gene, but although its symptoms include muscle weakness due to muscle atrophy, they are generally milder than DMD, and the progression of muscle weakness is slower, and in many cases, the disease develops in adulthood. The difference in clinical symptoms between DMD and BMD is thought to be due to whether the amino acid reading frame when dystrophin mRNA is translated into dystrophin protein is destroyed or maintained by the mutation (Non-Patent Document 1). In other words, in DMD, functional dystrophin protein is hardly expressed due to a mutation that shifts the amino acid reading frame, but in BMD, part of the exon is deleted due to the mutation, but the amino acid reading frame is maintained, so that incomplete but functional dystrophin protein is produced.

[0005] Exon skipping is expected to be a treatment for DMD. This method involves modifying splicing to repair the amino acid reading frame of dystrophin mRNA and induce the expression of dystrophin protein with partial recovery of function (Non-Patent Document 2). The amino acid sequence portion targeted by exon skipping is lost. Therefore, the dystrophin protein expressed by this treatment is shorter than normal, but the amino acid reading frame is maintained, so the function of stabilizing muscle cells is partially retained. Therefore, it is expected that exon skipping will cause DMD to exhibit symptoms similar to milder BMD. After animal experiments using mice and dogs, clinical trials of the exon skipping method are being conducted on human DMD patients.

[0006] Exon skipping can be induced by binding of antisense nucleic acids targeting either or both of the 5' or 3' splice sites, or the inside of an exon. An exon is included in an mRNA only when both splice sites are recognized by the spliceosome complex. Therefore, exon skipping can be induced by targeting a splice site with an antisense nucleic acid. It is also believed that binding of an SR protein to an exon splicing enhancer (ESE) is necessary for an exon to be recognized by the splicing machinery, and exon skipping can also be induced by targeting the ESE.

[0007] Since the mutations in the dystrophin gene differ among DMD patients, antisense nucleic acids according to the location and type of gene mutation are required. So far, Steve Wilton et al. of the University of Western Australia have created antisense nucleic acids that induce exon skipping for all 79 exons (Non-Patent Document 3), and Annemieke Aartsma-Rus et al. of the Netherlands have created antisense nucleic acids that induce exon skipping for 39 types of exons (Non-Patent Document 4).

[0008] It is believed that about 10% of all DMD patients can be treated by skipping the 53rd exon (hereinafter referred to as "exon 53"). In recent years, several research institutions have reported on research targeting exon 53 of the dystrophin gene for exon skipping (Patent Documents 1 to 4; Non-Patent Documents 5 and 6). [Prior art documents] [Patent documents]

[0009] [Patent Document 1] International Publication WO 2006 / 000057 [Patent Document 2] International Publication WO 2004 / 048570 [Patent Document 3] U.S. Patent Publication US 2010 / 0168212 [Patent Document 4] International Publication WO 2010 / 048586 [Non-patent literature]

[0010] [Non-Patent Document 1] Monaco AP et al., Genomics 1988; 2: p. 90-95 [Non-Patent Document 2] Matsuo M., Brain Dev 1996; 18: p. 167-172 [Non-Patent Document 3] Wilton SD et al., Molecular Therapy 2007: 15: p. 1288-96 [Non-Patent Document 4] Annemieke Aartsma-Rus et al., (2002) Neuromuscular Disorders 12: S71-S77 [Non-Patent Document 5] Linda J. Popplewell et al., (2010) Neuromuscular Disorders, vol. 20, no. 2, p. 102-10 [Non-Patent Document 6] Bladen CL et al., Human Mutation (2015) 36:395-402 Summary of the Invention

[0011] The present invention is, but not limited to, the following. <1> A pharmaceutical composition for treating Duchenne muscular dystrophy in a human patient, comprising an antisense oligomer having a base sequence complementary to a sequence consisting of the 36th to 56th nucleotides from the 5' end of the 53rd exon of the human dystrophin gene, or a pharma- ceutical acceptable salt or hydrate thereof, The pharmaceutical composition, wherein the treatment comprises intravenously administering 40 mg / kg to 80 mg / kg of the antisense oligomer or a pharma- ceutical acceptable salt or hydrate thereof to the human patient once a week. <2> The antisense oligomer or a pharma- ceutical acceptable salt or hydrate thereof is administered intravenously to the human patient at 40 mg / kg once a week. <1> The pharmaceutical composition described in <3> The antisense oligomer or a pharma- ceutical acceptable salt or hydrate thereof is administered intravenously to the human patient at 80 mg / kg once a week. <1> The pharmaceutical composition described in <4> The human patient has a mutation in the dystrophin gene that results in the deletion of any one of exons selected from the group consisting of exons 43-52, 45-52, 47-52, 48-52, 49-52, 50-52, and 52. <1> The pharmaceutical composition described in <5> The expression of dystrophin protein in the human patient prior to treatment is 1% or less than that in a healthy individual as measured by Western blotting or mass spectrometry. <1> The pharmaceutical composition according to <6> said human patient exhibiting no expression of dystrophin protein prior to treatment; <5> The pharmaceutical composition described in <7> The sequence of the base portion of the antisense oligomer consists of the sequence shown in SEQ ID NO: 3. <1> The pharmaceutical composition described in <8> The antisense oligomer or a pharma- ceutical acceptable salt or hydrate thereof is viltolarsen or an equivalent thereof. <1> The pharmaceutical composition described in <9> The antisense oligomer or a pharma- ceutical acceptable salt or hydrate thereof is contained in a concentration of 2.5 to 500 mg / ml or 10 to 100 mg / ml. <1> The pharmaceutical composition described in <10> The antisense oligomer or a pharma- ceutical acceptable salt or hydrate thereof is contained in a concentration of 25 mg / ml. <1> The pharmaceutical composition described in <11> The antisense oligomer or a pharma- ceutical acceptable salt or hydrate thereof is contained in a concentration of 50 mg / ml. <1> The pharmaceutical composition described in <12> The composition further comprises at least one component selected from the group consisting of an isotonicity agent, a pH adjuster, and a solvent. <1> The pharmaceutical composition described in <13> The isotonicity agent is at least one selected from the group consisting of sodium chloride, potassium chloride, glucose, fructose, maltose, sucrose, lactose, mannitol, sorbitol, xylitol, trehalose, and glycerin. <12> The pharmaceutical composition described in <14> The pH adjuster is at least one selected from the group consisting of hydrochloric acid, sodium hydroxide, citric acid, lactic acid, phosphates (sodium hydrogen phosphate, sodium dihydrogen phosphate, potassium dihydrogen phosphate) and monoethanolamine. <12> or <13> The pharmaceutical composition described in <15> The solvent is water. <12> ~ <14> 2. The pharmaceutical composition according to claim 1 , <16> The aqueous solution contains an antisense oligomer at a concentration of 2.5 to 500 mg / ml or 10 to 100 mg / ml, sodium chloride at a concentration of 8 to 10 mg / ml, and has a pH of 7.2 to 7.4. <1> The pharmaceutical composition described in <17> The treatment produces at least one effect selected from the group consisting of the following (1) to (6): <1> The pharmaceutical composition according to claim 1, (1) the mean expression level of dystrophin protein in the skeletal muscle of patients is increased by more than nine-fold compared to baseline after 24 weeks of treatment; (2) The change in velocity derived from rise time (TTSTAND) was ≥-0.055 / s at week 25 after 24 weeks of treatment compared to baseline; (3) change in speed, calculated from time to 10-meter run / walk (TTRW), of ≥-0.025 meters / second at week 25 after 24 weeks of treatment compared to baseline; (4) The change in speed measured by time to climb four steps (TTCLIMB) was greater than or equal to -0.060 steps / second at 25 weeks after 24 weeks of treatment compared to baseline; (5) A change in North Star Ambulation Assessment (NSAA) score of ≥-2.2 points at week 25 after 24 weeks of treatment compared to baseline; and (6) Change in 6-minute walk test (6MWT) score compared to baseline is ≥-7.5 meters at 25 weeks after 24 weeks of treatment. <18> When the treatment is administered to a human patient with Duchenne muscular dystrophy aged 7 to 9 years for 84 weeks, at least one effect selected from the group consisting of the following (1) to (6) is produced. <1> The pharmaceutical composition according to claim 1, (1) Less than 20% of patients will lose the ability to stand by the 85th week of treatment; (2) Fewer than 10% of patients were unable to climb four steps by the 85th week of treatment; (3) Fewer than 10% of patients will lose the ability to walk independently by 85 weeks from the start of treatment; (4) no age-related decline in 10-meter running / walking speed from the start of treatment through 85 weeks; (5) no age-related decrease in 4-step stair climbing speed was observed from the start of treatment through 85 weeks; and (6) No age-related decrease in standing speed is observed within 85 weeks from the start of treatment. <19> When the treatment is administered to a human patient with Duchenne muscular dystrophy aged 10 to 12 for 84 weeks, at least one effect selected from the group consisting of the following (1) to (6) is produced: <1> The pharmaceutical composition according to claim 1, (1) Less than 60% of patients lose the ability to stand by 85 weeks after starting treatment; (2) Fewer than 50% of patients were unable to climb four steps by the 85th week of treatment; (3) Fewer than 50% of patients will lose the ability to walk independently by 85 weeks from the start of treatment; and (4) No age-related decrease in 10-meter running / walking speed is observed from the start of treatment through 85 weeks. (5) A period of increased velocity of 4-step stair climbing was observed between the start of treatment and 85 weeks; and (6) A period of increased rising speed is observed between the start of treatment and 85 weeks. <20> A pharmaceutical composition comprising an antisense oligomer having a base sequence complementary to a sequence consisting of the 36th to 56th nucleotides from the 5' end of the 53rd exon of the human dystrophin gene, or a pharma- ceutical acceptable salt or hydrate thereof, A method for treating Duchenne muscular dystrophy, comprising intravenously administering the antisense oligomer or a pharma- ceutical acceptable salt or hydrate thereof to a human patient at 40 mg / kg to 80 mg / kg once a week. <20-1> The method of treatment produces at least one effect according to claim 17, at least one effect according to claim 18, or at least one effect according to claim 19. <20> The treatment method described above. <21> An antisense oligomer or a pharma- tically acceptable salt or hydrate thereof, comprising a base sequence complementary to a sequence consisting of the 36th to 56th nucleotides from the 5'-end of the 53rd exon of the human dystrophin gene, for use in a method for treating Duchenne muscular dystrophy in a human patient, The antisense oligomer or a pharma- ceutical acceptable salt or hydrate thereof is administered intravenously to the human patient at 40 mg / kg to 80 mg / kg once a week. The antisense oligomer or a pharma- ceutically acceptable salt or hydrate thereof. <21-1> The administration produces at least one effect according to claim 17, at least one effect according to claim 18, or at least one effect according to claim 19. <21> 2. The antisense oligomer according to claim 1, or a pharma- ceutically acceptable salt or hydrate thereof. <22> Use of an antisense oligomer having a base sequence complementary to a sequence consisting of the 36th to 56th nucleotides from the 5' end of the 53rd exon of the human dystrophin gene, or a pharma- ceutical acceptable salt or hydrate thereof, for the manufacture of a pharmaceutical composition for treating Duchenne muscular dystrophy in a human patient, comprising: The antisense oligomer or a pharma- ceutical acceptable salt or hydrate thereof is administered intravenously to the human patient at 40 mg / kg to 80 mg / kg once a week. The above uses.

[0012] In addition, in another aspect, the present invention is as follows, but not limited to: [1]: A method for treating a subject having Duchenne muscular dystrophy suitable for treatment with exon 53 skipping, comprising the step of intravenously administering NS-065 / NCNP-01 to the subject at a dose of about 40 mg / kg / week. [2]: A method for treating a subject having Duchenne muscular dystrophy suitable for treatment with exon 53 skipping, comprising the step of intravenously administering NS-065 / NCNP-01 to the subject at a dose of about 80 mg / kg / week. [3]: A method for treating a subject with Duchenne muscular dystrophy suitable for treatment with exon 53 skipping, comprising the step of intravenously administering NS-065 / NCNP-01 to the subject at a dose of 40 mg / kg / week to 80 mg / kg / week. [4]: What is administered is NS-065 / NCNP-01 at a concentration of ≥2.5 mg / mL and ≤500 mg / mL; and Sodium chloride at a concentration of 8.55 mg / mL to 9.45 mg / mL as an isotonic agent is an aqueous solution containing The method of claim 1, wherein the aqueous solution has a pH of about 7.3. [5]: What is administered is NS-065 / NCNP-01 at a concentration of ≥2.5 mg / mL and ≤500 mg / mL; and Sodium chloride at a concentration of 8.55 mg / mL to 9.45 mg / mL as an isotonic agent is an aqueous solution containing The method of claim 2, wherein the aqueous solution has a pH of about 7.3. [6]: What is administered is NS-065 / NCNP-01 at a concentration of ≥2.5 mg / mL and ≤500 mg / mL; and Sodium chloride at a concentration of 8.55 mg / mL to 9.45 mg / mL as an isotonic agent is an aqueous solution containing The method of claim 3, wherein the aqueous solution has a pH of about 7.3. [7]: A method for inducing dystrophin protein production in a subject having Duchenne muscular dystrophy amenable to treatment with exon 53 skipping, comprising the step of intravenously administering NS-065 / NCNP-01 to the subject at a dose of about 40 mg / kg / week. [8]: A method for inducing dystrophin protein production in a subject having Duchenne muscular dystrophy amenable to treatment with exon 53 skipping, comprising the step of intravenously administering NS-065 / NCNP-01 to the subject at a dose of about 80 mg / kg / week. [9]: A method for inducing dystrophin protein production in a subject having Duchenne muscular dystrophy amenable to treatment with exon 53 skipping, comprising the step of intravenously administering NS-065 / NCNP-01 to the subject at a dose of at least 40 mg / kg / week and not exceeding 80 mg / kg / week.

[10] : What is administered? NS-065 / NCNP-01 at a concentration of ≥2.5 mg / mL and ≤500 mg / mL; and Sodium chloride at a concentration of 8.55 mg / mL to 9.45 mg / mL as an isotonic agent is an aqueous solution containing The method according to [7], wherein the aqueous solution has a pH of about 7.3.

[11] : What is administered? NS-065 / NCNP-01 at a concentration of ≥2.5 mg / mL and ≤500 mg / mL; and Sodium chloride at a concentration of 8.55 mg / mL to 9.45 mg / mL as an isotonic agent is an aqueous solution containing The method of claim 8, wherein the aqueous solution has a pH of about 7.3.

[12] : What is administered is NS-065 / NCNP-01 at a concentration of ≥2.5 mg / mL and ≤500 mg / mL; and Sodium chloride at a concentration of 8.55 mg / mL to 9.45 mg / mL as an isotonic agent is an aqueous solution containing The method of claim 9, wherein the aqueous solution has a pH of about 7.3. In the above [1] to

[12] , NS-065 / NCNP-01 (also referred to as "Viltolarsen" in this specification) may be an equivalent product. In the above [1] to

[12] , the subject may be a human patient.

[0013] The present invention provides a pharmaceutical composition for treating Duchenne muscular dystrophy, which has a stable composition of Viltolarsen. In addition, the pharmaceutical composition containing Viltolarsen provides a method and dosage of Viltolarsen that effectively treats Duchenne muscular dystrophy and is safe for human patients. The pharmaceutical composition can effectively alleviate symptoms of Duchenne muscular dystrophy with low side effects. [Brief description of the drawings]

[0014] [Figure 1] The design of the US Phase 2 dose-finding study NS-065 / NCNP-01-201 is shown. [Diagram 2] 1 shows the results of measuring the expression level of de novo dystrophin protein in skeletal muscle using Western blotting. [Diagram 3] The design of the US / Canadian Phase 2 dose-finding study, NS-065 / NCNP-01-201, is shown. [Figure 4] Comparison of changes from baseline in chronofunctional tests over 24 weeks is shown. In the five graphs, "Viltolarsen" is the International Nonproprietary Name (INN) of NS-065 / NCNP-01. [Diagram 5] The results of stability evaluation of viltolarsen in Britton-Robinson buffer (pH 3 to 11) are shown. [Figure 6] The results of a stability evaluation of viltolarsen in potassium phosphate-borax buffer (pH 6-9) are shown. [Figure 7] The results of a study of pH adjusters at 121°C are shown. [Figure 8] Graphs showing changes from baseline in the results of each motor function test. [Figure 9] 1 is a graph showing the results of the 6-minute walking test in each subject in the viltolarsen administration groups (40 mg / kg administration group and 80 mg / kg administration group) up to 85 weeks (84 weeks after the first administration). [Figure 10]This is a graph showing the North Star Walking Test scores for each subject in the Viltolarsen administration groups (40 mg / kg group and 80 mg / kg group) up to Week 85 (84 weeks after the first administration). [Figure 11] This is a graph showing the results of the rise time test speed for each test patient in the viltolarsen administration groups (40 mg / kg administration group and 80 mg / kg administration group) up to 85 weeks (84 weeks after the first administration). [Figure 12] This is a graph showing the results of the speed of the 4-step stair climbing time test for each subject in the Viltolarsen administration groups (40 mg / kg administration group and 80 mg / kg administration group) up to 85 weeks (84 weeks after the first administration). [Figure 13] This is a graph showing the results of the 10 m walking / running test speed for each subject in the viltolarsen administration groups (40 mg / kg administration group and 80 mg / kg administration group) up to 85 weeks (84 weeks after the first administration). [Figure 14] This is a graph showing the correlation between the change in dystrophin expression level from baseline in the dystrophin quantification value by WB and the change in rise time rate from baseline in each patient in the viltolarsen administration group (40 mg / kg administration group and 80 mg / kg administration group) at 49 weeks (48 weeks after the first administration). [Figure 15] This is a graph showing the correlation between the change in dystrophin expression level from baseline in the dystrophin quantification value by WB and the change in speed from baseline in the 4-step stair climbing test in each patient in the viltolarsen treatment groups (40 mg / kg treatment group and 80 mg / kg treatment group) at 49 weeks (48 weeks after the first administration). [Figure 16] This is a graph showing the correlation between the change in dystrophin expression level from baseline in dystrophin quantification values ​​by WB and the change in speed from baseline in a 10-m walk / running test in each patient in the viltolarsen treatment groups (40 mg / kg treatment group and 80 mg / kg treatment group) at 49 weeks (48 weeks after the first administration). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0015] The present invention will be described in detail below. The following embodiments are merely illustrative for explaining the present invention, and are not intended to limit the present invention to these embodiments. The present invention can be embodied in various forms without departing from the gist of the present invention. All documents cited in this specification, as well as publications, patent publications, and other patent documents, are incorporated herein by reference. This specification also includes the contents of the specifications and drawings of the U.S. provisional patent application (US62 / 690,270) filed on June 26, 2018, from which this application claims priority, and the U.S. provisional patent application (US62 / 739,386) filed on October 1, 2018, from which this application claims priority.

[0016] I. First Form In a first embodiment, the present invention provides a pharmaceutical composition for treating Duchenne muscular dystrophy. That is, the pharmaceutical composition of the present invention is a pharmaceutical composition for treating Duchenne muscular dystrophy in a human patient, comprising an antisense oligomer (hereinafter also referred to as "the oligomer of the present invention") consisting of a base sequence complementary to a sequence consisting of the 36th to 56th nucleotides from the 5'-end of the 53rd exon of the human dystrophin gene, or a pharma- ceutical acceptable salt or hydrate thereof, The pharmaceutical composition is provided, wherein the treatment comprises intravenously administering 40 mg / kg to 80 mg / kg of the antisense oligomer or a pharma- ceutical acceptable salt or hydrate thereof to the human patient once a week.

[0017] [Exon 53 of the human dystrophin gene] In the present invention, the term "gene" includes not only genomic genes, but also cDNA, pre-mRNA and mRNA. Preferably, the gene is a pre-mRNA, i.e., pre-mRNA. In the human genome, the human dystrophin gene is located at locus Xp21.2. The human dystrophin gene has a size of 3.0 Mbp, making it the largest known human gene. However, the coding region of the human dystrophin gene is only 14 kb, and the coding region is distributed within the dystrophin gene as 79 exons (Roberts, RG., et al., Genomics, 16: 536-538 (1993)). The pre-mRNA, which is the transcript of the human dystrophin gene, is spliced ​​to generate a 14 kb mature mRNA. The nucleotide sequence of the mature mRNA of the human wild-type dystrophin gene is known (GenBank Accession No. NM_004006). The nucleotide sequence of exon 53 of the human wild-type dystrophin gene is shown in SEQ ID NO:1.

[0018] The pharmaceutical composition of the present invention contains an antisense oligomer (the oligomer of the present invention) consisting of a base sequence complementary to a sequence consisting of the 36th to 56th nucleotides from the 5' end of the 53rd exon of the human dystrophin gene, or a pharma- ceutically acceptable salt or hydrate thereof. Here, the oligomer of the present invention was produced for the purpose of modifying a protein encoded by a DMD-type dystrophin gene into a BMD-type dystrophin protein by skipping exon 53 of the human dystrophin gene. Therefore, exon 53 of the dystrophin gene that is the target of exon skipping by the oligomer of the present invention includes not only the wild type but also mutant types.

[0019] Specifically, the exon 53 of the mutant human dystrophin gene can be a polynucleotide having an identity of 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, 99.1% or more, 99.2% or more, 99.3% or more, 99.4% or more, 99.5% or more, 99.6% or more, 99.7% or more, 99.8% or more, or 99.9% or more to the base sequence of SEQ ID NO: 1. In the present specification, the term "polynucleotide" refers to DNA or RNA.

[0020] The identity of nucleotide sequences can be determined using the algorithm BLAST (Basic Local Alignment Search Tool) by Carlin and Altschul (Proc. Natl. Acad. Sci. USA 872264-2268, 1990; Proc Natl Acad Sci USA 90: 5873, 1993). Programs called BLASTN and BLASTX based on the BLAST algorithm have been developed (Altschul SF, et al: J Mol Biol 215: 403, 1990). When analyzing nucleotide sequences using BLASTN, the parameters are, for example, score = 100 and wordlength = 12. When using the BLAST and Gapped BLAST programs, the default parameters of each program are used.

[0021] In the present specification, the term "complementary base sequence" is not limited to a base sequence that forms a Watson-Crick pair with the target base sequence, but also includes a base sequence that forms a wobble base pair. Here, the Watson-Crick pair means a base pair in which a hydrogen bond is formed between adenine-thymine, adenine-uracil, and guanine-cytosine, and the wobble base pair means a base pair in which a hydrogen bond is formed between guanine-uracil, inosine-uracil, inosine-adenine, and inosine-cytosine. In addition, the term "complementary base sequence" does not have to have 100% complementarity with the target base sequence, and may contain, for example, one, two, three, four, or five non-complementary bases relative to the target base sequence, or may be a base sequence that is one, two, three, four, or five bases shorter than the target base sequence.

[0022] An example of a sequence consisting of the 36th to 56th nucleotides from the 5' end of exon 53 (SEQ ID NO: 2) and a complementary base sequence thereto (SEQ ID NO: 3) are shown in Table 1 below.

[0023] [Table 1]

[0024] Here, thymine "T" and uracil "U" are interchangeable, and since there is essentially no effect on the exon skipping activity of the oligomer of the present invention whether it is "T" or "U," in this application, even if "T" in the base sequence shown in the SEQ ID NO is "U," it will be shown by the same SEQ ID NO. Therefore, the sequences disclosed in this application necessarily include both the sequence of "T" and the sequence of "U."

[0025] Therefore, the oligomer of the present invention may have a base sequence of its base portion consisting of the sequence shown in SEQ ID NO: 3. In addition, the oligomer of the present invention may not have a base sequence that is 100% complementary to the target sequence, so long as it enables skipping of exon 53 of the human dystrophin gene. For example, the oligomer of the present invention may contain 1, 2, 3, 4, or 5 non-complementary bases to the target sequence SEQ ID NO: 2, or may have a base sequence that is 1, 2, 3, 4, or 5 bases shorter than the target base sequence.

[0026] Whether or not exon 53 skipping of the human dystrophin gene has occurred can be confirmed by introducing the oligomer of the present invention into dystrophin-expressing cells (e.g., human rhabdomyosarcoma cells), amplifying the region surrounding exon 53 of mRNA of the human dystrophin gene from the total RNA of the dystrophin-expressing cells by RT-PCR, and subjecting the PCR amplification product to nested PCR or sequence analysis. Alternatively, whether or not skipping has occurred can be confirmed by measuring the amount of exon 53 in a sample derived from a patient to which the oligomer of the present invention has been administered, using techniques such as RT-PCR, Western blotting, and mass spectrometry. The skipping efficiency can be calculated according to the following formula based on the measured values ​​of "A" and "B", by recovering mRNA of the human dystrophin gene from test cells, measuring the polynucleotide amount "A" of the band in which exon 53 was skipped and the polynucleotide amount "B" of the band in which exon 53 was not skipped. Skipping efficiency (%) = A / ( A + B ) × 100

[0027] The oligomer of the present invention may be an oligonucleotide, a morpholino oligomer, or a peptide nucleic acid (PNA) oligomer. The oligomer of the present invention is preferably a morpholino oligomer.

[0028] The oligonucleotide (hereinafter referred to as "the oligonucleotide of the present invention") is an oligomer of the present invention having nucleotides as its constituent units, and such nucleotides may be any of ribonucleotides, deoxyribonucleotides, or modified nucleotides. A modified nucleotide refers to a ribonucleotide or deoxyribonucleotide in which the nucleic acid base, sugar moiety, and phosphate linkage moiety constituting the ribonucleotide or deoxyribonucleotide have been modified in whole or in part.

[0029] Examples of nucleic acid bases include adenine, guanine, hypoxanthine, cytosine, thymine, uracil, and modified bases thereof. Examples of such modified bases include pseudouracil, 3-methyluracil, dihydrouracil, 5-alkylcytosine (e.g., 5-methylcytosine), 5-alkyluracil (e.g., 5-ethyluracil), 5-halouracil (5-bromouracil), 6-azapyrimidine, 6-alkylpyrimidine (6-methyluracil), 2-thiouracil, 4-thiouracil, 4-acetylcytosine, 5-(carboxyhydroxymethyl) Examples of the amino acid sequence include, but are not limited to, uracil, 5'-carboxymethylaminomethyl-2-thiouracil, 5-carboxymethylaminomethyluracil, 1-methyladenine, 1-methylhypoxanthine, 2,2-dimethylguanine, 3-methylcytosine, 2-methyladenine, 2-methylguanine, N6-methyladenine, 7-methylguanine, 5-methoxyaminomethyl-2-thiouracil, 5-methylaminomethyluracil, 5-methylcarbonylmethyluracil, 5-methyloxyuracil, 5-methyl-2-thiouracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid, 2-thiocytosine, purine, 2,6-diaminopurine, 2-aminopurine, isoguanine, indole, imidazole, and xanthine.

[0030] Modifications of the sugar moiety include, for example, modifications of the 2'-position of ribose and modifications of other parts of the sugar. Modifications of the 2'-position of ribose include, for example, modifications in which the -OH group at the 2'-position of ribose is replaced with OR, R, R'OR, SH, SR, NH2, NHR, NR2, N3, CN, F, Cl, Br, or I. Here, R represents alkyl or aryl. R' represents alkylene. Modifications of other sugar moieties include, but are not limited to, for example, substitution of the O at the 4' position of ribose or deoxyribose with S, and bridging of the 2' and 4' positions of the sugar, such as LNA (Locked Nucleic Acid) or ENA (2'-O,4'-C-Ethylene-bridged Nucleic Acids).

[0031] Modifications of the phosphate linkage moiety include, for example, modifications that replace the phosphodiester bond with a phosphorothioate bond, a phosphorodithioate bond, an alkylphosphonate bond, a phosphoramidate bond, or a boranophosphate bond (Enya et al: Bioorganic & Medicinal Chemistry, 2008, 18, 9154-9160) (see, for example, Patent Republished Publications Nos. 2006 / 129594 and 2006 / 038608).

[0032] The alkyl is preferably a linear or branched alkyl having 1 to 6 carbon atoms. Specific examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, n-hexyl, and isohexyl. The alkyl may be substituted, and examples of such substituents include halogen, alkoxy, cyano, and nitro, and 1 to 3 of these may be substituted.

[0033] The cycloalkyl is preferably a cycloalkyl having a carbon number of 5 to 12. Specific examples include cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclodecyl, and cyclododecyl.

[0034] Examples of halogen include fluorine, chlorine, bromine, and iodine.

[0035] Examples of the alkoxy include linear or branched alkoxy having 1 to 6 carbon atoms, such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, n-pentyloxy, isopentyloxy, n-hexyloxy, isohexyloxy, etc. In particular, alkoxy having 1 to 3 carbon atoms is preferred.

[0036] The aryl is preferably an aryl having 6 to 10 carbon atoms. Specific examples include phenyl, α-naphthyl, and β-naphthyl. Phenyl is particularly preferred. The aryl may be substituted, and examples of such substituents include alkyl, halogen, alkoxy, cyano, and nitro, and 1 to 3 of these may be substituted.

[0037] The alkylene is preferably a linear or branched alkylene having 1 to 6 carbon atoms, specifically, for example, methylene, ethylene, trimethylene, tetramethylene, pentamethylene, hexamethylene, 2-(ethyl)trimethylene, and 1-(methyl)tetramethylene.

[0038] The acyl may include linear or branched alkanoyl or aroyl. The alkanoyl may include, for example, formyl, acetyl, 2-methylacetyl, 2,2-dimethylacetyl, propionyl, butyryl, isobutyryl, pentanoyl, 2,2-dimethylpropionyl, hexanoyl, etc. The aroyl may include, for example, benzoyl, toluoyl, naphthoyl. Such aroyl may be substituted at a substitutable position, or may be substituted with an alkyl.

[0039] In an embodiment in which the oligomer of the present invention is an oligonucleotide, the oligonucleotide may preferably have as its constituent unit a group represented by the following general formula, in which the -OH group at the 2'-position of ribose is substituted with methoxy and the phosphate bond moiety is a phosphorothioate bond. [ka] (In the formula, Base represents a nucleic acid base.)

[0040] Such oligonucleotides can be easily synthesized using various automated synthesizers (e.g., AKTA oligopilot plus 10 / 100 (GE Healthcare)), or can be produced by outsourcing to a third party (e.g., Promega or Takara).

[0041] When the oligomer of the present invention is a morpholino oligomer, the morpholino oligomer may have a group represented by the following general formula as a constituent unit. [ka] (In the formula, Base has the same meaning as defined above; W represents a group represented by any of the following formulas: [ka] (Wherein, X is -CHR 1 , -O-CH2R 1 , -S-CH2R 1 , -NR 2 R 3 or F; R 1 represents H, alkyl; R 2 and R 3 are the same or different and represent H, alkyl, cycloalkyl, or aryl; Y1 is 0, S, CH2 or NR 1 represents; Y2 is 0, S or NR 1 represents; Z represents 0 or S.

[0042] The morpholino oligomer is preferably an oligomer having a group represented by the following formula as a constituent unit (phosphorodiamidate morpholino oligomer (hereinafter referred to as "PMO")). [ka] (In the formula, Base, R 2 , R 3 has the same meaning as above.)

[0043] Morpholino oligomers can be prepared, for example, according to WO 1991 / 009033 or WO 2009 / 064471. In particular, PMOs can be prepared according to the methods described in WO 2009 / 064471 or according to the methods set forth below.

[0044] One embodiment of the PMO is, for example, a compound represented by the following general formula (I) (hereinafter, referred to as PMO(I)). [ka] [In the formula, each Base, R 2 , R 3 is as defined above; n is any integer in the range of 1 to 99, and preferably any integer in the range of 18 to 28.

[0045] PMO (I) can be produced according to a known method, and the compounds and reagents used are not particularly limited as long as they are generally used in the production of PMOs. The production can be carried out by a liquid phase method or a solid phase method (using a manual or commercially available solid phase automatic synthesizer). When producing PMO by a solid phase method, a method using an automatic synthesizer is preferable from the viewpoints of simplification of the operation procedure and accuracy of synthesis.

[0046] A peptide nucleic acid is an oligomer of the present invention having as a constituent unit a group represented by the following general formula: [ka] [In the formula, Base has the same meaning as defined above.]

[0047] Peptide nucleic acids can be prepared, for example, according to the following documents: 1)PE Nielsen, M. Egholm, RH Berg, O. Buchardt, Science, 254, 1497 (1991) 2) M. Egholm, O. Buchardt, PE Nielsen, RH Berg, Jacs., 114, 1895 (1992) 3)KL Dueholm, M. Egholm, C. Behrens, L. Christensen, HF Hansen, T. Vulpius, KH Petersen, RH Berg, PE Nielsen, O. Buchardt,J. Org. Chem., 59, 5767 (1994) 4) L. Christensen, R. Fitzpatrick, B. Gildea, KH Petersen, HF Hansen, T. Koch, M. Egholm, O. Buchardt, PE Nielsen, J. Coull, RH Berg, J. Pept. Sci., 1, 175 (1995) 5) T. Koch, HF Hansen, P. Andersen, T. Larsen, HG Batz, K. Otteson, H. Orum, J. Pept. Res., 49, 80 (1997)

[0048] Furthermore, the 5'-end of the oligomer of the present invention may be any of the groups represented by the following chemical formulas (1) to (3), preferably (3) -OH. [ka] Hereinafter, the groups represented by (1), (2) and (3) above will be referred to as "group (1)", "group (2)" and "group (3)", respectively.

[0049] Examples of pharma- ceutically acceptable salts of the oligomers of the invention include alkali metal salts, such as sodium, potassium, and lithium salts, alkaline earth metal salts, such as calcium and magnesium salts; metal salts, such as aluminum, iron, zinc, copper, nickel, and cobalt salts; ammonium salts; t-octylamine salts, dibenzylamine salts, morpholine salts, glucosamine salts, phenylglycine alkyl ester salts, ethylenediamine salts, N-methylglucamine salts, guanidine salts, diethylamine salts, triethylamine salts, dicyclohexylamine salts, N,N'-dibenzylethylenediamine salts, chloroprocaine salts, procaine salts, diethanolamine salts, N-benzyl-phenethylamine salts, piperazine salts, and the like. Examples of suitable salts include organic amine salts such as tetramethylammonium salts and tris(hydroxymethyl)aminomethane salts; hydrohalide salts such as hydrofluoride, hydrochloride, hydrobromide and hydroiodide; inorganic acid salts such as nitrate, perchlorate, sulfate and phosphate; lower alkane sulfonate salts such as methanesulfonate, trifluoromethanesulfonate and ethanesulfonate; arylsulfonate salts such as benzenesulfonate and p-toluenesulfonate; organic acid salts such as acetate, malate, fumarate, succinate, citrate, tartrate, oxalate and maleate; amino acid salts such as glycine salt, lysine salt, arginine salt, ornithine salt, glutamate and aspartate. These salts can be prepared by known methods. Alternatively, the oligomer of the present invention may be in the form of a hydrate.

[0050] In another embodiment, the oligomer of the present invention may be Viltolarsen or an equivalent thereof. Viltolarsen is the International Nonproprietary Name (INN) of NS-065 / NCNP-01. In this specification, NS-065 / NCNP-01 is also referred to as NS-065 / NCNP-01, NS-065 / NCNP-01(Viltolarsen) or Viltolarsen.

[0051] NS-065 / NCNP-01 (Viltolarsen) is an antisense oligonucleotide drug substance for the treatment of Duchenne muscular dystrophy (DMD) patients suitable for treatment by exon 53 skipping. NS-065 / NCNP-01 (Viltolarsen) is a compound disclosed in U.S. Pat. No. 9,079,934B2 as "PMO No. 8", and the sequence of the base portion is represented by SEQ ID NO: 35 (5'-CCTCCGGTTC TGAAGGTGTTC-3', SEQ ID NO: 3 herein) and has a 5' end of -OH. U.S. Pat. No. 9,079,934B2 is incorporated herein in its entirety by reference. U.S. Pat. No. 9,079,934B2 also discloses a method for synthesizing PMO No. 8, i.e., NS-065 / NCNP-01 (Viltolarsen).

[0052] NS-065 / NCNP-01 (Viltolarsen) has a morpholino backbone that is expected to provide greater safety than phosphorothioate oligonucleotides. For example, the development of the phosphorothioate oligonucleotide drisapersen (by BioMarin) has been suspended due to safety concerns, while the morpholino oligonucleotide eteplirsen (Exondys51® by Sarepta) has been approved by the FDA. Both drisapersen and eteplirsen are for DMD patients suitable for treatment by exon 51 skipping. Eteplirsen is disclosed in U.S. Patent No. 9,506,058 B2, the entire contents of which are incorporated herein by reference.

[0053] As disclosed in U.S. Patent No. 9,079,934 B2, NS-065 / NCNP-01 (Viltolarsen) was designed to specifically exhibit exon 53 skipping activity to generate functional dystrophin protein in DMD patients lacking specific exons, including exons 43-52, 45-52, 47-52, 48-52, 49-52, 50-52, or 52. Examples of DMD-causing mutations that are theoretically treatable by skipping specific exons are shown in Table 3 of Aartsma-Rus et al., 2002. The contents of the Aartsma-Rus et al. publication are incorporated by reference in their entirety (Annemieke Aartsma-Rus, Mattie Bremmer-Bout, Anneke AM Janson, Johan T. den Dunnen, Gert-Jan B. van Ommen, and Judith CT van Deutekom, "Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy," Neuromuscular Disorders, Vol. 12, pp. S71-S77 (2002)).

[0054] An "equivalent" of Viltolarsen is a generic drug of Viltolarsen or a compound that is an active ingredient thereof. Such an equivalent has been approved for manufacture and sale under the Pharmaceutical Affairs Law without undergoing clinical trials based on the safety and efficacy confirmed in clinical trials of Viltolarsen, and is expected to have exon 53 skipping activity similar to that of Viltolarsen. In one embodiment, an "equivalent" of Viltolarsen includes a drug having the same base sequence as Viltolarsen, and whose nucleic acid base, sugar moiety, and phosphate binding moiety are all or partly modified in the same manner as Viltolarsen or modified differently. The embodiments of these modifications are the same as those described above. In addition, an "equivalent" of Viltolarsen may be in the form of a free form, a pharma- ceutically acceptable salt, or a hydrate.

[0055] 2. Pharmaceutical Compositions The pharmaceutical composition of the present invention may be in the form of an aqueous solution. The pharmaceutical composition of the present invention may contain the oligomer of the present invention, or a pharma- ceutical acceptable salt thereof, or a hydrate thereof, at a concentration of 2.5 to 500 mg / ml, 5 to 450 mg / ml, 10 to 400 mg / ml, 15 to 350 mg / ml, 20 to 300 mg / ml, 20 to 250 mg / ml, 20 to 200 mg / ml, 20 to 150 mg / ml, 20 to 100 mg / ml, 20 to 50 mg / ml, 20 to 40 mg / ml, 20 to 30 mg / ml, 23 to 27 mg / ml, 24 to 26 mg / ml, or 25 mg / ml. Alternatively, the pharmaceutical composition of the present invention may contain the oligomer of the present invention or a pharma- ceutical acceptable salt thereof, or a hydrate thereof at a concentration of 10 to 100 mg / ml, 15 to 95 mg / ml, 20 to 80 mg / ml, 25 to 75 mg / ml, 30 to 70 mg / ml, 35 to 65 mg / ml, 40 to 60 mg / ml, 45 to 55 mg / ml, 47 to 53 mg / ml, 48 to 52 mg / ml, 49 to 51 mg / ml, or 50 mg / ml.

[0056] In the pharmaceutical composition of the present invention, the concentration of Viltolarsen in the aqueous solution may be changed. To prepare an aqueous solution of Viltolarsen, for example, 250 mg of Viltolarsen may be mixed with 0.5 mL to 100 mL of water (corresponding to a Viltolarsen concentration of 2.5 mg / mL to 500 mg / mL), more preferably with 1 mL to 50 mL of water (corresponding to a Viltolarsen concentration of 5 mg / mL to 250 mg / mL), and most preferably with 5 mL to 10 mL of water (corresponding to a Viltolarsen concentration of 25 mg / mL to 50 mg / mL).

[0057] The pharmaceutical composition of the present invention is administered intravenously. The pharmaceutical composition of the present invention can be administered in the form of, for example, an injection (including a drip infusion).

[0058] The pharmaceutical composition of the present invention may further comprise at least one component selected from an isotonicity agent, a pH adjuster, and a solvent.

[0059] The isotonicity agent contained in the pharmaceutical composition of the present invention may be at least one selected from sodium chloride, potassium chloride, glucose, fructose, maltose, sucrose, lactose, mannitol, sorbitol, xylitol, trehalose, and glycerin.

[0060] A 10 mL aqueous solution suitable for injection containing 250 mg of viltolarsen may contain, as an isotonicity agent, 72.0 mg to 108.0 mg of sodium chloride (corresponding to a sodium chloride concentration of 7.2 mg / mL to 10.8 mg / mL), more preferably 81.0 mg to 99.0 mg of sodium chloride (corresponding to a sodium chloride concentration of 8.1 mg / mL to 9.9 mg / mL), and most preferably 85.5 mg to 94.5 mg of sodium chloride (corresponding to a sodium chloride concentration of 8.55 mg / mL to 9.45 mg / mL).

[0061] Phosphate buffer may be used as the isotonicity agent. Such phosphate buffer includes citrate buffer, lactate buffer, acetate buffer, etc. Also, sugar (other than glucose) may be used as the isotonicity agent. Examples of such sugar include sorbitol and mannitol. When preparing a composition containing viltolarsen, multiple isotonicity agents may be used as well.

[0062] The pH adjuster contained in the pharmaceutical composition of the present invention may be at least one selected from hydrochloric acid, sulfuric acid, phosphoric acid, acetic acid, sodium hydroxide, potassium hydroxide, triethanolamine, citric acid, lactic acid, phosphates (sodium hydrogen phosphate, sodium dihydrogen phosphate, potassium dihydrogen phosphate), and monoethanolamine.

[0063] When a phosphate buffer is used for the oligomer of the present invention, such as Viltolarsen, the concentration of the phosphate buffer is preferably less than 100 mM. Thus, the pharmaceutical composition of the present invention may be adjusted to have a phosphate buffer concentration of 90 mM or less, 80 mM or less, 70 mM or less, 60 mM or less, 50 mM or less, 40 mM or less, 30 mM or less, 20 mM or less, 10 mM or less, or 5 mM or less, or may not contain a phosphate buffer.

[0064] The solvent contained in the pharmaceutical composition of the present invention may be water.

[0065] The pH of the aqueous solution suitable for injection containing viltolarsen may be from 6.0 to 8.5, more preferably from 6.5 to 8.0, and most preferably from 7.0 to 7.5. The oligomer of the present invention is stable over a wide range of pH, but the pharmaceutical composition of the present invention is preferably adjusted to pH 7.0 to 7.5, 7.0 to 7.4, 7.1 to 7.5, 7.1 to 7.4, 7.2 to 7.5, 7.2 to 7.4, 7.3 to 7.5, 7.3 to 7.4, or 7.3.

[0066] The pharmaceutical composition of the present invention may be an aqueous solution containing the oligomer of the present invention at a concentration of 2.5 to 500 mg / ml or 10 to 100 mg / ml, sodium chloride at a concentration of 8 to 10 mg / ml, and having a pH of 7.2 to 7.4. Alternatively, the pharmaceutical composition of the present invention may be an aqueous solution containing the oligomer of the present invention at a concentration of 25 mg / ml and adjusted to pH 7.3 without buffer, in which the pH is adjusted using hydrochloric acid and / or sodium hydroxide.

[0067] As an example of the pharmaceutical composition of the present invention, an injectable composition containing 250 mg of Viltolarsen used in the US / Canada Phase 2 clinical program is shown in Table 2. The pharmaceutical composition shown in Table 2 is hereinafter referred to as "NS-065 / NCNP-01 (Viltolarsen) Injection 250 mg."

[0068] [Table 2]

[0069] In addition, in the composition of "NS-065 / NCNP-01 (Viltolarsen) injection 250 mg", the amount of water for injection and the amount of sodium chloride as an isotonicity agent may be reduced to about half, and the total amount may be 5 mL. The pharmaceutical composition containing Viltolarsen at a concentration of 50 mg / mL according to such a composition is also included in the present invention.

[0070] The volume of the aqueous solution containing Viltolarsen may be increased or decreased as long as the concentrations of NS-065 / NCNP-01 and the tonicity agent used, as well as the weight ratio between Viltolarsen and the tonicity agent used, remain equivalent to those described above.

[0071] The composition containing Viltolarsen may also contain a carrier to promote the delivery of Viltolarsen to muscle tissue. Such a carrier is not particularly limited as long as it is pharma- ceutically acceptable, and may include, for example, a cationic carrier (e.g., cationic liposome and cationic polymer) and a carrier using a virus envelope. Examples of cationic liposomes include liposomes containing 2-O-(2-diethylaminoethyl)carbamoyl-1,3-O-dioleoylglycerol and phospholipids as essential components, Oligofectamine (registered trademark) (manufactured by Thermo Fisher Scientific), Lipofectin (registered trademark) (manufactured by Thermo Fisher Scientific), Lipofectamine (registered trademark) (manufactured by Thermo Fisher Scientific), Lipofectamine (registered trademark) 2000 (manufactured by Thermo Fisher Scientific), DMRIE-C (manufactured by Thermo Fisher Scientific), GeneSilencer (registered trademark) (manufactured by Gene Therapy Systems), TransMessenger (registered trademark) (manufactured by QIAGEN), and TransIT-TKO (registered trademark). Examples of cationic polymers include JetSI (registered trademark) (manufactured by GeneX India Bioscience) and Jet-PEI (registered trademark) (polyethyleneimine, GeneX India Bioscience). Examples of carriers using a viral envelope include GenomeOne (registered trademark) (HVJ-E liposome, manufactured by Ishihara Sangyo Kaisha, Ltd.).

[0072] Furthermore, the pharmaceutical composition of the present invention may contain an emulsifier (for example, a fatty acid having 6 to 22 carbon atoms or a pharma- ceutical acceptable salt thereof, albumin, dextran) or a stabilizer (for example, cholesterol, phosphatidic acid).

[0073] In the pharmaceutical composition of the present invention containing viltolarsen and a carrier, the weight ratio of viltolarsen to the carrier (i.e., carrier / viltolarsen) may vary depending on the type of carrier used, and is suitably in the range of 0.1 to 100, preferably in the range of 1 to 50, and more preferably in the range of 10 to 20.

[0074] Aqueous solutions containing viltolarsen may be administered to a patient by intravenous infusion or drip.

[0075] 3. Efficacy, Effects and Dosage When the pharmaceutical composition of the present invention is used for treatment, the oligomer of the present invention or a pharma- ceutically acceptable salt or hydrate thereof is intravenously administered to a human patient at 40 mg / kg to 80 mg / kg once a week (hereinafter referred to as "the dosage and administration of the present invention"). Alternatively, the dosage and administration of the present invention may be such that the oligomer of the present invention or a pharma- ceutically acceptable salt or hydrate thereof is intravenously administered to a human patient at 40 mg / kg once a week. Alternatively, the dosage and administration of the present invention may be such that the oligomer of the present invention or a pharma- ceutically acceptable salt or hydrate thereof is intravenously administered to a human patient at 80 mg / kg once a week. Here, in the dosage unit "mg / kg", the numerator "mg" represents the amount of the oligomer of the present invention or a pharma- ceutically acceptable salt or hydrate thereof in milligrams, and the denominator "kg" represents the body weight of a human patient in kilograms.

[0076] NS-065 / NCNP-01 (Viltolarsen) injection 250 mg was developed for weekly intravenous infusion to treat DMD patients suitable for treatment with exon 53 skipping. The US / Canada Phase 2 clinical program was designed to evaluate two doses of Viltolarsen: 40 mg / kg / week and 80 mg / kg / week, where kg is the patient's body weight. For example, 40 mg / kg / week for a patient weighing 40 kg means that the patient is administered 1,600 mg (=40 mg x 40) of Viltolarsen once a week.

[0077] 4. Disease DMD is a muscle disease caused by loss-of-function mutations in the dystrophin gene, resulting in the loss of dystrophin protein in patients' muscles (Hoffman et al., 1987). The dystrophin gene is located on the X chromosome and exhibits a high spontaneous mutation rate, with the incidence of DMD being 1 in 5,000 live-born males in all studied world populations. A recent evaluation showed that 10.1% of 7,149 DMD patients evaluated in a global patient database were suitable for treatment with exon 53 skipping (Bladen et al., 2015). Clinical symptoms typically present at early school age (between 4 and 6 years of age), with affected boys showing difficulty in physically matching their peers due to proximal muscle weakness (e.g., difficulty climbing stairs or difficulty running). Difficulty rising from the floor is present in most patients who achieve standing using the typical Gower's movements (i.e., using hand support on the feet, knees, and thighs to achieve standing) (Hoffman EP, Brown RH, and Kunkel LM. (1987). Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51, 919-928.およびBladen CL, Salgado D, Monges S, Foncuberta ME, Kekou K, Kosma K, Dawkins H, Lamont L, Roy AJ, Chamova T, Guergueltcheva V, Chan S, Korngut L, Campbell C, Dai Y, Wang J, Barisic N, Brasic N, Bratie P, Lahde-McK, Walter-McK O, Karcagi V, Garami M, Viswanathan V, Bayat F, Buccella F, Kimura E, Koeks Z, van den Bergen JC, Rodrigues M, Roxburgh R, Lusakowska A, Kostera-Pruszczyk A, Zimowski J, Santos R, Neagu E, Artemieva S, Rasic VM, Vojin D, Posada, Posada, Jean Posada, C. PY, Joncourt F, Diaz-Manera J, Gallardo E, Karaduman AA, Topaloglu H, El Sherif R, Stringer A, Shatillo AV, Martin AS, Peay HL, Bellgard MI, Kirschner J, Flanigan KM, Straub V, Bushby K, Verschuuren J, Aartsma-R Cus A, Lochmuller H (2015). The TREAT-NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations. Hum Mutat. 36(4): 395-402)。.

[0078] Muscle tissue in DMD patients exhibits chronic inflammation, accompanied by episodes of muscle degeneration and regeneration, leading to muscle wasting, disability, and premature death. Patients typically lose ambulation by the second decade of life and require assistance with many aspects of daily living by the third decade. The disease usually leads to death in adolescence or early adulthood, although the use of ventilator-assisted devices can sometimes extend life expectancy into the fourth decade, but rarely into the fifth decade.

[0079] DMD gene mutations in subjects can be detected by using multiplex ligation-dependent probe amplification (MLPA) (Murugan et al., 2010). The entire contents of the article by Murugan et al. are incorporated by reference (Sakthivel Murugan SM, Arthi Chandramohan and Bremadesam Raman Lakshmi, “Use of multiplex ligation-dependent probe amplification (MLPA) for Duchenne muscular dystrophy (DMD) gene mutation analysis,” Indian Journal of Medical Research, Vol. 132, pp. 303-311 (September 2010).).

[0080] Human patients to be treated with the pharmaceutical composition of the present invention (hereinafter referred to as "patients to be treated with the present invention") are not particularly limited as long as they are patients diagnosed by a physician as having DMD. In one embodiment, the patient may have a mutation in the dystrophin gene in which any one of exons selected from the group consisting of exons 43-52, 45-52, 47-52, 48-52, 49-52, 50-52, or 52 is deleted.

[0081] The subject of the present invention may be characterized in that the expression of dystrophin protein is 1% or less of that of a healthy person (100%) as measured by Western blotting or mass spectrometry before treatment with the pharmaceutical composition of the present invention or the oligomer of the present invention. Here, the "healthy person" refers to a person who does not have a disease related to dystrophin protein. The expression level of dystrophin protein in a healthy person may be a generally known value, or a value obtained from an individual healthy person. The subject of the present invention may be characterized in that the expression of dystrophin protein is not observed before treatment with the pharmaceutical composition of the present invention or the oligomer of the present invention. "No expression of dystrophin protein is observed" means that the expression level of dystrophin protein is the same as that of a negative control, or is below the detection limit, as measured by Western blotting or mass spectrometry. The Western blotting and mass spectrometry are not particularly limited as long as they are methods commonly used in the field. As an example of Western blotting and mass spectrometry, the experimental method in this embodiment can be referred to.

[0082] 5.Treatment theory DMD is a severe genetic muscle disorder, most commonly caused by the deletion of one or more exons from the dystrophin gene, resulting in out-of-frame amino acid translation. This results in the patient not expressing functional dystrophin protein, which is important for muscle function. A less severe form of the disorder, Becker muscular dystrophy (BMD), most commonly occurs when one or more exons are absent in the dystrophin gene, but the remaining exons are translated in-frame. Patients with BMD generally have a slower disease progression and a lesser degree of disability. Medical treatment for DMD patients generally includes glucocorticoid treatment to delay the onset of symptoms in limb muscles and respiratory support. There is significant unmet medical need for patients with DMD, as outlined in the FDA’s February 2018 final guidance, “Duchenne Muscular Dystrophy and Related Dystrophinopathies: Developing Drugs for Treatment Guidance for Industry.” (available at: https: / / www.fda.gov / downloads / Drugs / GuidanceComplianceRegulatoryInformation / Guidances / UCM450229.pdf).

[0083] One therapeutic approach to treat DMD patients is to use an "exon skipping" strategy, aiming to produce a functional dystrophin protein and shift DMD patients to a BMD phenotype. Exon skipping induces the skipping of the exon next to the deleted exon, which can restore the amino acid reading frame (Cirak et al., 2011; Voit et al., 2014; Yokota et al., 2012). Skipping exon 53 results in the expression of a dystrophin protein that is slightly shorter than normal but retains partial functional activity. NS-065 / NCNP-01 (Viltolarsen) injection 250mg is expected to shift the DMD phenotype to a milder form of disease in BMD, slowing disease progression and improving patients' quality of life. (Cirak S, Arechavala-Gomeza V, Guglieri M, Feng L, Torelli S, Anthony K, Abbs S, Garralda ME, Bourke J, Wells DJ, Dickson G, Wood MJ, Wilton SD, Straub V, Kole R, Shrewsbury SB, Sewry C, Morgan JE, Bushby K, Muntoni F. (2011). Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet 378: 595-605., Voit T, Topaloglu H, Straub V, Muntoni F, Deconinck N, Campion G, De Kimpe SJ, Eagle M, Guglieri M, Hood S, Liefaard L, Lourbakos A, Morgan A, Nakielny J, Quarcoo N, Ricotti V, Rolfe K, Servais L, Wardell C, Wilson R, Wright P, Kraus JE. (2014). Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomized, placebo-controlled phase 2 study. Lancet Neurol. 13(10): 987-96. and Yokota T, Nakamura A, Nagata T, Saito T, Kobayashi M, Aoki Y, Echigoya Y, Partridge T, Hoffman EP, Takeda S. (2012). Extensive and Prolonged Restoration of Dystrophin Expression with Vivo-Morpholino-Mediated Multiple Exon Skipping in Dystrophic Dogs. Nucleic Acid Ther 22(5): 306-15.). .

[0084] Therefore, by administering the pharmaceutical composition of the present invention to a human patient according to the above-mentioned dosage regimen of the present invention, it is possible to treat DMD. Here, "treating" means alleviating the symptoms of DMD in a patient.

[0085] A treatment using the pharmaceutical composition of the present invention according to the dosage and administration method of the present invention can produce at least one effect selected from the group consisting of the following (1) to (6) (the values ​​in parentheses indicate the mean ± standard deviation): (1) the mean expression level of dystrophin protein in the skeletal muscle of patients is increased by more than nine-fold compared to baseline after 24 weeks of treatment; (2) The change in velocity determined by rise time (TTSTAND) was greater than or equal to -0.055 / s or greater than or equal to 0.024 ± 0.075 seconds at 25 weeks after 24 weeks of treatment compared to baseline; (3) change in speed, calculated from time to 10-meter run / walk (TTRW), from baseline to week 25 after 24 weeks of treatment of ≥-0.025 m / s or ≥0.227 ± 0.251 m / s; (4) The change in speed, calculated from the time to climb four steps (TTCLIMB), compared to baseline was greater than or equal to -0.060 movements / second or greater than or equal to 0.032 ± 0.088 movements / second at 25 weeks after 24 weeks of treatment; (5) A change in North Star Ambulation Assessment (NSAA) score of ≥-2.2 or ≥0.8±2.9 at week 25 after 24 weeks of treatment compared to baseline; and (6) Change in 6-minute walk test (6MWT) score compared to baseline is ≥-7.5 meters or ≥28.9 ± 36.3 meters at 25 weeks after 24 weeks of treatment.

[0086] In the above (1) to (6), "baseline" refers to the average value in a group of untreated patients, and "change" in (2) to (6) refers to the change in the average value.

[0087] In one embodiment, when the pharmaceutical composition of the present invention is administered to a human patient with Duchenne muscular dystrophy aged 7 to 9 years for 84 weeks in accordance with the above-described dosage regimen of the present invention, at least one effect selected from the group consisting of the following (7) to (12) can be achieved: (7) Less than 20% of patients lose the ability to stand by the 85th week of treatment; (8) The rate of patients unable to climb four steps from the start of treatment to 85 weeks is less than 10%; (9) Less than 10% of patients will lose the ability to walk independently by the 85th week of treatment; (10) No age-related decline in 10-meter running / walking speed from the start of treatment through 85 weeks; (11) no age-related decline in 4-step stair climbing speed from the start of treatment through 85 weeks; and (12) No age-related decrease in rising speed is observed within 85 weeks from the start of treatment. The effects of (7) to (12) above may occur at any time point between weeks 1 and 85, between weeks 1 and 80, between weeks 1 and 75, between weeks 1 and 70, between weeks 1 and 65, or between weeks 1 and 60, with the week when treatment begins being defined as week 1.

[0088] In one embodiment, administration of the pharmaceutical composition of the present invention to a human patient with Duchenne muscular dystrophy aged 10 to 12 years according to the above-described dosage regimen of the present invention produces at least one effect selected from the group consisting of the following (13) to (18): (13) Less than 60% of patients lose the ability to stand by the 85th week of treatment; (14) Fewer than 50% of patients were unable to climb four steps by the 85th week of treatment; (15) Less than 50% of patients will lose the ability to walk independently by the 85th week of treatment; and (16) No age-related decline in 10-meter running / walking speed is observed through 85 weeks from the start of treatment. (17) A period of increased velocity of 4-step stair climbing was observed by the 85th week of treatment; and (18) A period of increased rising speed is observed between the start of treatment and 85 weeks. The effects of (13) to (18) above may occur at any time point between weeks 1 and 85, between weeks 1 and 80, between weeks 1 and 75, between weeks 1 and 70, between weeks 1 and 65, or between weeks 1 and 60, with the week when treatment begins being defined as week 1.

[0089] That is, the pharmaceutical composition of the present invention can produce at least one of the effects related to the above (1) to (18).

[0090] II. The second form The present invention, in a second aspect thereof, comprises A pharmaceutical composition comprising an antisense oligomer having a base sequence complementary to a sequence consisting of the 36th to 56th nucleotides from the 5' end of the 53rd exon of the human dystrophin gene, or a pharma- ceutical acceptable salt or hydrate thereof, The present invention provides a method for treating Duchenne muscular dystrophy, which comprises intravenously administering the antisense oligomer or a pharma- ceutical acceptable salt or hydrate thereof to the human patient at 40 mg / kg to 80 mg / kg once a week (hereinafter referred to as the "treatment method of the present invention"). The meaning of each component related to the treatment method of the present invention is the same as that explained for the components related to the pharmaceutical composition of the present invention in the section "I. First embodiment." Furthermore, the treatment method of the present invention can produce at least one of the effects (1) to (18) described in the subsection "5. Treatment theory" of the section "I. First embodiment."

[0091] III. The third form Furthermore, the present invention, in a third aspect thereof, An antisense oligomer or a pharma- tically acceptable salt or hydrate thereof, comprising a base sequence complementary to a sequence consisting of the 36th to 56th nucleotides from the 5'-end of the 53rd exon of the human dystrophin gene, for use in a method for treating Duchenne muscular dystrophy in a human patient, The antisense oligomer or a pharma- ceutical acceptable salt or hydrate thereof is administered intravenously to the human patient at 40 mg / kg to 80 mg / kg once a week. The present invention provides the antisense oligomer or a pharma- ceutical acceptable salt or hydrate thereof (hereinafter referred to as the "use-specific form of the present invention"). The meaning of each component in the use-specific embodiment of the present invention is the same as that explained for the components in the pharmaceutical composition of the present invention in the section "I. First embodiment." In addition, the use specific aspect of the present invention can produce at least one of the effects (1) to (18) described in the subsection "5. Treatment theory" of the section "I. First aspect."

[0092] IV. The Fourth Form Furthermore, the present invention, in a fourth aspect thereof, Use of an antisense oligomer having a base sequence complementary to a sequence consisting of the 36th to 56th nucleotides from the 5' end of the 53rd exon of the human dystrophin gene, or a pharma- ceutical acceptable salt or hydrate thereof, for the manufacture of a pharmaceutical composition for treating Duchenne muscular dystrophy in a human patient, comprising: The antisense oligomer or a pharma- ceutical acceptable salt or hydrate thereof is administered intravenously to the human patient at 40 mg / kg to 80 mg / kg once a week. The above-mentioned use (hereinafter referred to as "the Swiss-type use of the present invention") is provided. The meaning of each component related to the Swiss-type use of the present invention is the same as that explained for the components related to the pharmaceutical composition of the present invention in the section "I. First embodiment." In addition, the Swiss-type use of the present invention can produce at least one of the effects (1) to (18) described in the subsection "5. Treatment theory" of the section "I. First embodiment."

[0093] The present invention will be described in more detail below with reference to examples, but the present invention is not limited to the scope shown in the examples. EXAMPLES

[0094] Manufacturing Example

[0095] (1) Preparation of 4-{[(2S,6R)-6-(4-benzamido-2-oxopyrimidin-1-yl)-4-tritylmorpholin-2-yl]methoxy}-4-oxobutanoic acid supported on aminomethylpolystyrene resin Step 1: Preparation of 4-{[(2S,6R)-6-(4-benzamido-2-oxopyrimidin-1(2H)-yl)-4-tritylmorpholin-2-yl]methoxy}-4-oxobutanoic acid Under an argon atmosphere, 22.0 g of N-{1-[(2R,6S)-6-(hydroxymethyl)-4-tritylmorpholin-2-yl]-2-oxo-1,2-dihydropyrimidin-4-yl}benzamide and 7.04 g of 4-dimethylaminopyridine (4-DMAP) were suspended in 269 mL of dichloromethane, 5.76 g of succinic anhydride was added, and the mixture was stirred at room temperature for 3 hours. 40 mL of methanol was added to the reaction solution, which was then concentrated under reduced pressure. The residue was subjected to an extraction operation using ethyl acetate and a 0.5 M aqueous solution of potassium dihydrogen phosphate. The obtained organic layer was washed with a 0.5 M aqueous solution of potassium dihydrogen phosphate, water, and saturated saline in that order. The obtained organic layer was dried over sodium sulfate and concentrated under reduced pressure to obtain 25.9 g of the target product.

[0096] Step 2: Preparation of aminomethyl polystyrene resin supported 4-{[(2S,6R)-6-(4-benzamido-2-oxopyrimidin-1-yl)-4-tritylmorpholin-2-yl]methoxy}-4-oxobutanoic acid 23.5 g of 4-{[(2S,6R)-6-(4-benzamido-2-oxopyrimidin-1(2H)-yl)-4-tritylmorpholin-2-yl]methoxy}-4-oxobutanoic acid was dissolved in 336 mL of pyridine (dehydrated), and 4.28 g of 4-DMAP and 40.3 g of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride were added. Then, 25.0 g of aminomethyl polystyrene resin 1% DVB crosslinked (Tokyo Chemical Industry Co., Ltd., A1543) and 24 mL of triethylamine were added, and the mixture was shaken at room temperature for 4 days. After the reaction, the resin was filtered. The obtained resin was washed with pyridine, methanol, and dichloromethane in that order, and dried under reduced pressure. 150 mL of tetrahydrofuran (dehydrated), 15 mL of acetic anhydride, and 15 mL of 2,6-lutidine were added to the obtained resin, and the mixture was shaken at room temperature for 2 hours. The resin was collected by filtration, washed with pyridine, methanol and dichloromethane in this order, and dried under reduced pressure to obtain 33.7 g of the desired product. The loading amount of the target compound was determined by measuring the molar amount of trityl per gram of resin using a known method at 409 nm UV absorbance, and the loading amount of the resin was 397.4 μmol / g.

[0097] UV measurement conditions Equipment: U-2910 (Hitachi) Solvent: methanesulfonic acid Wavelength: 265 nm Epsilon value: 45000

[0098] (2) Manufacturing of PMO No.8 PMO No. 8 has a target sequence of “positions 36 to 56” in exon 53, the group at the 5′ end is “group (3),” and the sequence of the base portion is represented by SEQ ID NO:3. 2 g (800 μmol) of 4-{[(2S,6R)-6-(4-benzamido-2-oxopyrimidin-1(2H)-yl)-4-tritylmorpholin-2-yl]methoxy}-4-oxobutanoic acid (Reference Example 1) supported on aminomethyl polystyrene resin was transferred to a reaction vessel, 30 mL of dichloromethane was added, and the vessel was left to stand for 30 minutes. After washing twice with 30 mL of dichloromethane, the following synthesis cycle was started. The desired morpholino monomer compound was added in each cycle so as to obtain the base sequence of the title compound.

[0099] [Table 3] The deblocking solution used was a mixture of trifluoroacetic acid (2 equivalents) and triethylamine (1 equivalent) dissolved in a dichloromethane solution containing 1% (v / v) ethanol and 10% (v / v) 2,2,2-trifluoroethanol to a concentration of 3% (w / v). The neutralizing solution used was a solution of N,N-diisopropylethylamine dissolved in a dichloromethane solution containing 25% (v / v) 2-propanol to a concentration of 5% (v / v). The coupling solution A used was a solution of a morpholino monomer compound dissolved in 1,3-dimethyl-2-imidazolidinone containing 10% (v / v) N,N-diisopropylethylamine to a concentration of 0.15 M. The coupling solution B used was a solution of N,N-diisopropylethylamine dissolved in 1,3-dimethyl-2-imidazolidinone to a concentration of 10% (v / v). The capping solution used was a solution of 20% (v / v) acetic anhydride and 30% (v / v) 2,6-lutidine in dichloromethane.

[0100] The aminomethylpolystyrene resin carrying the PMO synthesized above was collected from the reaction vessel and dried under reduced pressure at room temperature for more than 2 hours. The PMO carried on the dried aminomethylpolystyrene resin was placed in a reaction vessel, 200 mL of 28% aqueous ammonia-ethanol (1 / 4) was added, and the mixture was stirred at 55°C for 15 hours. The aminomethylpolystyrene resin was filtered off and washed with 50 mL of water-ethanol (1 / 4). The filtrate obtained was concentrated under reduced pressure. The residue obtained was dissolved in 100 mL of a mixed solvent of 20 mM acetic acid-triethylamine buffer (TEAA buffer) and acetonitrile (4 / 1), and filtered through a membrane filter. The filtrate obtained was purified by reverse phase HPLC. The conditions used were as follows.

[0101] [Table 4] Each fraction was analyzed, and the target product was recovered with 100 mL of acetonitrile-water (1 / 1), 200 mL of ethanol was added, and the mixture was concentrated under reduced pressure. The mixture was then dried under reduced pressure to obtain a white solid. 300 mL of 10 mM aqueous phosphoric acid was added to the obtained solid, and the solid was suspended. 10 mL of 2 M aqueous phosphoric acid was added, and the mixture was stirred for 15 minutes. 15 mL of 2 M aqueous sodium hydroxide was added to neutralize the solid. 15 mL of 2 M aqueous sodium hydroxide was added to make the solid alkaline, and the solid was filtered through a membrane filter (0.45 μm). The solid was washed with 100 mL of 10 mM aqueous sodium hydroxide to obtain the target product as an aqueous solution. The resulting aqueous solution containing the target substance was purified using an anion exchange resin column under the following conditions:

[0102] [Table 5] Each fraction was analyzed (HPLC) to obtain the target substance as an aqueous solution. The aqueous solution was neutralized by adding 225 mL of 0.1 M phosphate buffer (pH 6.0). The solution was filtered through a membrane filter (0.45 μm). Then, ultrafiltration was performed under the following conditions to desalt the solution.

[0103] [Table 6] The filtrate was concentrated to obtain about 250 mL of an aqueous solution. The obtained aqueous solution was filtered through a membrane filter (0.45 μm). The obtained aqueous solution was freeze-dried to obtain 1.5 g of the target compound as a white cotton-like solid. ESI-TOF-MS calculated value: 6924.82 Measurement: 6923.54 EXAMPLES

[0104] US Phase 2 study A Phase II dose-finding study, NS-065 / NCNP-01-201, was initiated under IND127474 in December 2016. The study was conducted under the title "Safety and Dose Finding Study of NS-065 / NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)" with ClinicalTrials.gov identification number NCT02740972. The protocol for this study is available at https: / / www.clinicaltrials.gov / ct2 / show / study / NCT02740972 and is incorporated by reference in its entirety. The primary objective of this study was to evaluate the safety of high-dose (80 mg / kg) and low-dose (40 mg / kg) NS-065 / NCNP-01 (Viltolarsen) delivered as an intravenous infusion in patients with Duchenne muscular dystrophy (DMD) suitable for treatment with exon 53 skipping, with additional objectives including tolerability, muscle function and strength, pharmacokinetics, and pharmacodynamics.

[0105] More specifically, this was a Phase II, multicenter, two-period, randomized, placebo-controlled, dose-finding study in which ambulatory boys aged 4 to 10 years with DMD received NS-065 / NCNP-01 (Viltolarsen) infusion once weekly for 24 weeks. Two dose-level cohorts were included. Period 1 was studied in a double-blind fashion. Patients were randomized to receive NS-065 / NCNP-01 (Viltolarsen) or placebo infusion once weekly for the first 4 weeks of participation (Period 1), and then NS-065 / NCNP-01 (Viltolarsen) infusion for weeks 5 to 24 (20 weeks of active treatment - Period 2). Analysis of safety data from Period 1 for the 40 mg / kg dose cohort was completed prior to enrolling patients in the 80 mg / kg dose cohort. Patients who completed the 24-week study were eligible to receive an open-label extension study.

[0106] Clinical efficacy was assessed at regularly scheduled study visits. All patients underwent a biceps muscle biopsy at baseline and a second muscle biopsy at week 24.

[0107] Safety was assessed by collecting adverse events (AEs), blood and urine laboratory tests, electrocardiograms (ECGs), vital signs, and physical examinations throughout the study. Serial blood samples were obtained at four study visits to assess the pharmacokinetics of NS-065 / NCNP-01 (Viltolarsen).

[0108] <Type of clinical trial: Intervention (clinical trial)> Actual registration: 16 participants. · Allocation: Randomized. · Intervention model: Parallel allocation. Masking: Quadruple (participant, caregiver, investigator, outcome assessor). ·Primary purpose: treatment. Actual exam start date: December 2016. · Initial completion date: March 2018.

[0109] Patient population and interventions Experiment: NS-065 / NCNP-01 (Viltolarsen) 40mg / kg Six patients with confirmed DMD and a genetic deletion amenable to treatment with exon 53 skipping received NS-065 / NCNP-01 (Viltolarsen) at a dose of 40 mg / kg administered intravenously once weekly for 24 weeks. Experimental: NS-065 / NCNP-01 (Viltolarsen) 80mg / kg Six patients with confirmed DMD and a genetic deletion amenable to treatment with exon 53 skipping received NS-065 / NCNP-01 (Viltolarsen) at a dose of 80 mg / kg administered intravenously once weekly for 24 weeks. Placebo comparator: Placebo Two or three patients in each dose group received placebo as an intravenous infusion once weekly for 4 weeks, followed by 20 weeks of open-label treatment.

[0110] <Selection criteria> Males aged 4 years or older but under 10 years old. Have a confirmed DMD mutation(s) in the dystrophin gene that is amenable to restoration of the dystrophin mRNA reading frame by exon 53 skipping therapy Able to walk independently without assistance Time to stand up, time to run / walk, and time to increase rating - At least 3 months of stable administration of glucocorticoids

[0111] <Exclusion criteria> -Acute illness within 4 weeks prior to the first dose of the study drug. Evidence of symptomatic cardiomyopathy (without excluding asymptomatic cardiac abnormalities at the time of investigation) ·Severe allergy or hypersensitivity to medications -Severe behavioral or cognitive problems that, in the opinion of the investigator, would prevent participation in the trial Any previous or ongoing medical condition, medical history, physical findings, or laboratory abnormalities that, in the opinion of the investigator, may affect safety, reduce the likelihood of successful completion of treatment and follow-up, or impair the assessment of the study results. -Currently taking or within 3 months of starting the study drug. Patients who underwent surgery within 3 months prior to the first anticipated dose of NS-065 / NCNP-01 (Viltolarsen) or who were scheduled for surgery during the study period -Patients who have previously participated in this study or who have been administered NS-065 / NCNP-01 (Viltolarsen) and previously participated in other studies

[0112] To recap, this was a 24-week, two-cohort study testing 40 mg / kg / week and 80 mg / kg / week doses in 16 male patients who were suitable for treatment with exon 53 skipping and stable on glucocorticoids for ≥3 months. Placebo-treated patients in each cohort underwent an initial 4-week randomization period as a control for adverse events (safety outcomes). Both placebo-treated and active-treated patients then continued in the study for the 20-week treatment period. In the NS-065 / NCNP-01-201 study, NS-065 / NCNP-01 (Viltolarsen) injections were administered in two dose cohorts, a low dose of 40 mg / kg / week and a high dose of 80 mg / kg / week, for 20–24 weeks to evaluate the effect on de novo expression of dystrophin protein (see Figure 1). The goal of Study NS-065 / NCNP-01-201 was to identify a safe and effective dose based on de novo expression of dystrophin protein in skeletal muscle measured using Western blot (WB) methodology (primary surrogate endpoint). Secondary surrogate endpoints included immunofluorescence (IF) staining and mass spectrometry detection of de novo dystrophin protein expression, as well as RT-PCR detection of de novo dystrophin mRNA levels. Several functional endpoints were also included as secondary endpoints for the Phase 2 study. The endpoints of Study NS-065 / NCNP-01-201 were as follows:

[0113] <Primary endpoint> Safety and tolerability of low-dose (40 mg / kg / week) and high-dose (80 mg / kg / week) intravenous (IV) administration of NS-065 / NCNP-01 (Viltolarsen) injection The induction of dystrophin protein in muscle was measured by Western blot after 20-24 weeks of treatment, as was the effect of low and high IV doses of NS-065 / NCNP-01 (Viltolarsen) injection.

[0114] In Figure 1, the timeline for "high dose: 80 mg / kg / week" shown in the lower half is offset later than the timeline for "low dose: 40 mg / kg / week" shown in the lower half, indicating that high dose administration was initiated only after safety had been confirmed at the low dose.

[0115] Measurements: 1. Induction of dystrophin mRNA in muscle as measured by real-time polymerase chain reaction for mRNA analysis (RT-PCR) (time frame 20-24 weeks of treatment) RT-PCR measures altered splicing of dystrophin RNA. In this method, mRNA is isolated from frozen muscle biopsies and reverse transcribed into cDNA. PCR primers are designed adjacent to exon 53 sites on the dystrophin mRNA. RT-PCR bands corresponding to specific versions of spliced ​​dystrophin mRNA are visualized by gel electrophoresis to compare the abundance of different mRNA isoforms. If the drug successfully binds to the RNA target, exon 53 is excluded from the resulting mRNA transcript. 2. Induced dystrophin protein in muscle as measured by Western blot for protein analysis. (Time frame: 20-24 weeks of treatment)

[0116] The primary biochemical outcome measurement is the measurement of drug-induced increase in dystrophin production by immunoblot (Western blot). Dystrophin immunoblot uses solubilized muscle biopsy cryosections, and proteins are fractionated by molecular weight via gel electrophoresis (SDS-PAGE), electroblotting to nitrocellulose, and then incubation of the nitrocellulose with an antibody to detect dystrophin protein. The immunoblot signal for dystrophin from the patient biopsy is then compared to the signal of a standard curve of dystrophin on the same gel (mixed DMD and normal control). This provides a semi-quantitative assessment of dystrophin content in muscle.

[0117] US Phase 2 Study: Efficacy Outcome Measure 1 The results obtained for outcome measure 1 (i.e., RT-PCR detection of de novo dystrophin mRNA levels) were as follows:

[0118] [Table 7]

[0119] Outcome Measure 2 The results obtained for outcome measure 2 (i.e., measurement of de novo dystrophin protein expression in skeletal muscle using Western blot) showed a 19.0-fold increase (40 mg / kg / week for 24 weeks) and a 9.8-fold increase (80 mg / kg / week for 24 weeks) from baseline, comparing the baseline mean value with the on-treatment mean value, and a 27.2-fold increase (40 and 80 mg / kg / week for 24 weeks), calculated as the mean percentage increase for each patient. The obtained data are summarized in Table 8 below and in Figure 2.

[0120] [Table 8]

[0121] The degree of dystrophin restoration with NS-065 / NCNP-01 (Viltolarsen) (40 or 80 mg / kg / week for 24 weeks) was conservatively approximately 3-7 or 8.8-9.7 times higher than the degree of restoration previously reported for Exondys51® (eteplirsen) (30 mg / kg / week for 48 and 180 weeks), a treatment suitable for exon 51 skipping launched by Sarepta Therapeutics in 2016. Specifically, for comparison, the corresponding western blot data for Exondys51® (eteplirsen) are shown below. In 3 of 16 patients who received NS-065 / NCNP-01 (Viltolarsen) for 24 weeks, dystrophin levels increased by more than 10% from baseline. Twelve of 16 patients treated with NS-065 / NCNP-01 (Viltolarsen) for 24 weeks showed an increase in dystrophin levels of 3% or more. Hoffman et al. reported that "among patients with Becker dystrophy and Duchenne's with abnormal dystrophin phenotype (<3% of normal levels of dystrophin), there was a clear correlation between the severity of the clinical phenotype and the results of the dystrophin assessment" (Eric P. Hoffman, et al., "Characterization of Dystrophin in Muscle-Biopsy Specimens from Patients with Duchenne's of Becker's Muscular Dystrophy." N. Engl. J. Med., 318: 1363-1368 (1988)).

[0122] Eteplirsen Western Blotting: 2.8-fold increase (from 0.16% to 0.44% at 30 mg / kg / week for 48 weeks). ("In 12 cases with evaluable results, dystrophin levels were 0.16% ± 0.12% (mean ± SD) of dystrophin levels in healthy subjects before treatment and 0.44% ± 0.43% (p < 0.05) after 48 weeks of EXONDYS51 treatment.") (Available at https: / / www.fda.gov / downloads / AdvisoryCommittees / CommitteesMeetingMaterials / PediatricAdvisoryCommittee / UCM557917.pdf) · eteplirsen Western blotting: 3.1-fold (change from 0.3% to 0.93%) (30 mg / kg / week for 180 weeks). ("Western blots from biopsies of the extensor digitorum brevis (EDB) averaged dystrophin levels at approximately 0.3% of normal, ranging from undetectable to approximately 1% or greater of normal." "By Western blot, the most accurate quantitative method used by the applicants, the average dystrophin level approximately 3.5 years after eteplirsen treatment was 0.93% ± 0.84% ​​of that in healthy subjects (mean ± standard deviation)) (Available at https: / / www.fda.gov / downloads / advisorycommittees / committeesmeetingmaterials / drugs / peripheralandcentralnervoussystemdrugsadvisorycommittee / ucm497063.pdf.) Eteplirsen Western blot: 0.93% at 180 weeks, range 0%-2.47% (30mg / kg / week, 180 weeks) (Kenji Rowel Q Lim, et al., “Eteplirsen in the treatment of Duchenne muscular dystrophy.” Drug Des. Devel. Ther., 11: 533-545 (2017) https: / / www.ncbi.nlm.nih.gov / pmc / articles / PMC5338848 / ). Furthermore, "In a 180-week study of eteplirsen, no difference in dose-response was observed in dystrophin production between weekly doses of 30 mg / kg and 50 mg / kg, suggesting that this approach may not be effective for other exons." (Kenji Rowel Q Lim, et al., "Eteplirsen in the treatment of Duchenne muscular dystrophy." Drug Des. Devel. Ther., 11: 533-545 (2017) https: / / www.ncbi.nlm.nih.gov / pmc / articles / PMC5338848 / )

[0123] Comparison with SRP-4053 (golodirsen; Sarepta), a morpholino oligonucleotide for DMD patients suitable for treatment with exon 53 skipping, also showed that Viltolarsen had a superior effect in terms of the amount of increase in dystrophin levels observed. Specifically, for comparison purposes, the corresponding Western blot data for SRP-4053 (golodirsen) obtained after 48 weeks of treatment rather than 24 weeks of treatment with Viltolarsen is shown below.

[0124] Golodirsen Western Blot: 0.095% to 1.019% (30 mg / kg for 48 weeks). ("The mean increase in dystrophin protein increased to 1.019% of normal compared to a mean baseline of 0.095% of normal (p<0.001) as measured by Western Blot (the primary biological endpoint of the study). This represents a 10.7-fold increase from baseline.") (Available at http: / / investorrelations.sarepta.com / news-releases / news-release-details / sarepta-therapeutics-announces-positive-results-its-study.) Golodirsen Western blot: min 0.09%, max 4.30% (30mg / kg / week for 48 weeks. 2 out of 25 patients had a dystrophin level increase of 3% or more (22nd International Congress of the World Muscle Society (3-7 October 2017, St. Malo, France), http: / / www.google.co.jp / url?sa=t&source=web&cd=2&ved=2ahUKEwid7ZTQ9OrbAhUETLwKHX3xDk8QFjABegQIARAB&url=http%3A%2F%2Finvestorrelations.sarepta.com%2Fstatic-files%2F64d8d897-2e4a-4119-80b4-115cbae17993&usg=AOvVaw1Amh1Mq1VauvLkPvYWfVdR).

[0125] US Phase 2 Study: Safety Safety data from 16 patients with DMD who received high and low doses of NS-065 / NCNP-01 (Viltolarsen) (40 mg / kg / week and 80 mg / kg / week) did not reveal any major concerns regarding study conduct, data quality, or participant safety. No participants discontinued treatment at 36 weeks. Specifically, there were no serious adverse events, no adverse events leading to discontinuation, and no drug-related adverse events. All adverse events were mild or moderate in severity. EXAMPLES

[0126] US / Canadian Phase 2 Study A Phase II dose-finding study, NS-065 / NCNP-01-201, was initiated under IND127474 in December 2016. The study was conducted under the title "Safety and Dose Finding Study of NS-065 / NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)" with ClinicalTrials.gov identification number NCT02740972. The protocol for this study is available at https: / / www.clinicaltrials.gov / ct2 / show / study / NCT02740972 and is incorporated by reference in its entirety. The primary objective of this study was to evaluate the safety of high-dose (80 mg / kg) and low-dose (40 mg / kg) NS-065 / NCNP-01 (Viltolarsen) delivered as an intravenous infusion in patients with Duchenne muscular dystrophy (DMD) suitable for treatment with exon 53 skipping, with additional objectives including tolerability, muscle function and strength, pharmacokinetics, and pharmacodynamics. More specifically, this was a Phase II, multicenter, two-period, randomized, placebo-controlled, dose-finding study in which ambulatory boys aged 4 to 10 years with DMD received NS-065 / NCNP-01 (Viltolarsen) infusion once weekly for 24 weeks. Two dose-level cohorts were included. Period 1 was studied in a double-blind fashion. Patients were randomized to receive NS-065 / NCNP-01 (Viltolarsen) or placebo infusion once weekly for the first 4 weeks of participation (Period 1), and then NS-065 / NCNP-01 (Viltolarsen) infusion for weeks 5 to 24 (20 weeks of active treatment - Period 2). Analysis of safety data from Period 1 for the 40 mg / kg dose cohort was completed prior to enrolling patients in the 80 mg / kg dose cohort. Patients who completed the 24-week study were eligible to receive an open-label extension study.

[0127] Clinical efficacy was assessed at regularly scheduled study visits. All patients underwent a biceps muscle biopsy at baseline and a second muscle biopsy at week 24.

[0128] Safety was assessed by collecting adverse events (AEs), blood and urine laboratory tests, electrocardiograms (ECGs), vital signs, and physical examinations throughout the study. Serial blood samples were obtained at four study visits to assess the pharmacokinetics of NS-065 / NCNP-01 (Viltolarsen).

[0129] <Type of clinical trial: Intervention (clinical trial)> Actual registration: 16 participants. · Allocation: Randomized. · Intervention model: Parallel allocation. Masking: Quadruple (participant, caregiver, investigator, outcome assessor). · Primary purpose: treatment. Actual exam start date: December 2016. · Initial completion date: March 2018.

[0130] Patient population and interventions Experiment: NS-065 / NCNP-01 (Viltolarsen) 40mg / kg Six patients with confirmed DMD and a genetic deletion amenable to treatment with exon 53 skipping received NS-065 / NCNP-01 (Viltolarsen) at a dose of 40 mg / kg administered intravenously once weekly for 24 weeks. Experimental: NS-065 / NCNP-01 (Viltolarsen) 80mg / kg Five patients with confirmed DMD and a genetic deletion amenable to treatment with exon 53 skipping received NS-065 / NCNP-01 (Viltolarsen) at a dose of 80 mg / kg administered intravenously once weekly for 24 weeks. Placebo comparator: Placebo Two patients in the 40 mg / kg dose group and three patients in the 80 mg / kg dose group received placebo as an intravenous infusion once weekly for 4 weeks, followed by 20 weeks of open-label treatment.

[0131] <Selection criteria> -Males aged 4 years or older at the time of consent and less than 10 years old at the time of the first intravenous infusion. Have a confirmed DMD mutation(s) in the dystrophin gene that is amenable to restoration of the dystrophin mRNA reading frame via exon 53 skipping therapy. Able to walk independently without assistance Patients who are judged by a motor function evaluator to be able to perform the evaluations of time to stand (TSTAND), time to run / walk 10 meters (TTRW), and time to climb 4 steps (TTCLIMB). - At least 3 months of stable administration of glucocorticoids

[0132] <Exclusion criteria> -Acute illness within 4 weeks prior to the first dose of the study drug. Evidence of symptomatic cardiomyopathy (without excluding asymptomatic cardiac abnormalities at the time of investigation) ·Severe allergy or hypersensitivity to medications -Severe behavioral or cognitive problems that, in the opinion of the investigator, would prevent participation in the trial Any previous or ongoing medical condition, medical history, physical findings or laboratory abnormalities that, in the opinion of the investigator, may affect safety, reduce the likelihood of successful completion of treatment and follow-up, or impair the assessment of the study results. -Currently taking or taking other investigational drugs within 3 months prior to starting the investigational drug Patients who underwent surgery within 3 months prior to the first anticipated dose of NS-065 / NCNP-01 (Viltolarsen) or who were scheduled for surgery during the study period -Patients who have previously participated in this study or in other studies in which NS-065 / NCNP-01 (Viltolarsen) was administered

[0133] To summarize again, this was a 24-week, two-cohort study testing 40 mg / kg / week and 80 mg / kg / week doses in 16 male patients who were suitable for exon 53 skipping treatment and stable on glucocorticoids for 3 months or more. Placebo-treated patients in each cohort underwent an initial 4-week randomization period as a control for adverse events (safety outcomes). Both placebo-treated and active-treated patients then continued in the study for the 20-week treatment period. In the NS-065 / NCNP-01-201 study, NS-065 / NCNP-01 (Viltolarsen) injection 250 mg was administered in two dose cohorts, a low dose of 40 mg / kg / week and a high dose of 80 mg / kg / week, for 20 to 24 weeks to evaluate the effect on de novo expression of dystrophin protein (see Figure 3). The goal of Study NS-065 / NCNP-01-201 was to identify a safe and effective dose based on de novo expression of dystrophin protein in skeletal muscle measured using Western blot (WB) techniques (a pry surrogate endpoint). Secondary surrogate endpoints included immunofluorescence (IF) staining and mass spectrometry detection of de novo dystrophin protein expression, as well as RT-PCR detection of de novo dystrophin mRNA levels. Several functional endpoints were also included as secondary endpoints for the Phase 2 study. The endpoints of Study NS-065 / NCNP-01-201 were as follows:

[0134] <Primary endpoint> Safety and tolerability of low-dose (40 mg / kg / week) and high-dose (80 mg / kg / week) intravenous (IV) administration of NS-065 / NCNP-01 (Viltolarsen) injection 250 mg The effect of low and high IV doses of NS-065 / NCNP-01 (Viltolarsen) injection 250mg was measured by Western blot on induction of dystrophin protein in muscle after 20-24 weeks of treatment. Blood drug concentration of NS-065 / NCNP-01 (Viltolarsen)

[0135] <Secondary endpoint> To evaluate the effect of low and high doses of NS-065 / NCNP-01 (Viltolarsen) injection, 250 mg, on the induction of dystrophin mRNA and protein in muscle after 20 to 24 weeks of treatment, as measured by mRNA analysis using RT-PCR, and protein analysis using immunofluorescence staining and mass spectrometry. To investigate the effects of low and high doses of NS-065 / NCNP-01 (Viltolarsen) injection 250mg intravenously on muscle strength, mobility, and functional exercise capacity after 20-24 weeks of treatment, time to stand (TSTAND), 10 meter run / walk time (TTRW), 4 step climb time (TTCLIMB), North Star Ambulation Assessment (NSAA), 6 minute walk test (6MWT), and quantitative muscle testing (QMT) were measured in comparison to matched natural history controls.

[0136] In Figure 3, the timeline for "high dose: 80 mg / kg / week" shown in the lower half is offset later than the timeline for "low dose: 40 mg / kg / week" shown in the upper half, indicating that high dose administration was initiated only after safety had been confirmed at the low dose.

[0137] US / Canada Phase 2 Secondary Endpoint: Chronofunctional testing compared to an external untreated natural history group (CINRG Duchenne Natural History Study (DNHS)) Patients enrolled in the US / Canadian Phase 2 study NS-065 / NCNP-01-201 were clinically assessed for muscle function at baseline, week 13, and week 25. No adjustment was made for the 4-week placebo period for the purposes of this study. These assessments included several types of time-function tests: supine rise time (TTSTAND); 10-meter run / walk time (TTRW); 4-step climb time (TTCLIMB); 6-minute walk test (6MWT); and North Star Ambulatory Assessment (NSAA). Changes over time were compared to disease trajectories in matched patients studied in the CINRG DNHS.

[0138] The CINRG DNHS is a study that followed 440 DMD patients over several years (total study period: approximately 10 years). CINRG stands for Cooperative International Neuromuscular Research Group, which is "a consortium of medical and scientific researchers from academic and research centers who share the common goal of positively impacting the lives of people with neuromuscular diseases and their families" (http: / / www.cinrgresearch.org / ). DNHS stands for Duchenne natural history study, and is the "largest prospective multicenter natural history study to date in Duchenne muscular dystrophy (DMD)" established by CINRG (http: / / www.cinrgresearch.org / Duchenne-Natural-history / ). McDonald CM, Henricson EK, Abresch RT, Han JJ, Escolar DM, Florence JM, Duong T, Arrieta A, Clemens PR, Hoffman EP, and Cnaan A, "CINRG Investigators. The cooperative international neuromuscular research group Duchenne natural history study - a longitudinal investigation in the era of glucocorticoid therapy: design of protocol and the methods used," Muscle Nerve., 48(1), 32-54 (2013). Henricson EK, Abresch RT, Cnaan A, Hu F, Duong T, Arrieta A, Han J, Escolar DM, Florence JM, Clemens PR, Hoffman EP, and McDonald CM, “CINRG Investigators.The cooperative international neuromuscular research group Duchenne natural history study: glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measures,” Muscle Nerve., 48(1), 55-67 (2013). and McDonald CM, Henricson EK, Abresch RT, Duong T, Joyce NC, Hu F, Clemens PR, Hoffman EP, Cnaan A, and Gordish-Dressman H, “CINRG Investigators. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study,” Lancet, 391(10119), 451-461 (2018)).

[0139] The NS-065 / NCNP-01-201 study was conducted by clinical sites participating in the CINRG network. Standard operating procedures (clinical manuals) and clinical assessor training protocols were highly similar to the NS-065 / NCNP-01-201 clinical trial and the CINRG DNHS. Matching of patients enrolled in NS-065 / NCNP-01-201 versus the CINRG DNHS was performed using the following criteria: Boys aged 4 to <10.5 years at baseline. Patients with ≥12 months of time function test data. Region: North America (USA, Canada). Steroids have been administered for at least 3 months and will be continued throughout the 12 / 24 month observation period. - Not participating in another clinical trial

[0140] A query of the CINRG DNHS database for patients matched to those enrolled in the NS-065 / NCNP-01-201 clinical trial did not identify dystrophin mutations amenable to treatment with exon 53 skipping, but excluded patients with exon 3-7 deletions and patients with dystrophin deletions amenable to treatment with exon 44 skipping, resulting in the 69 subjects shown in Table 9 below. The reason for excluding patients with exon 3-7 deletions and patients with dystrophin deletions amenable to treatment with exon 44 skipping is that these patients have been reported to have relatively mild symptoms.

[0141] [Table 9]

[0142] In the top row of Table 9, "exon 53 skip" refers to DMD patients suitable for treatment with exon 53 skipping, and "non-exon 53 skip" refers to all other patients (but note the exclusions above). In the bottom row of Table 9, "no large deletion / duplication" encompasses other categories such as point mutations (not suitable for treatment with exon skipping).

[0143] The number of CINRG DNHS patients with data on the 6MWT was smaller than the number of patients with other outcome measures because the 6MWT was added late to the CINRG DNHS protocol, limiting the amount of data compared with other time-function tests.

[0144] A comparison of disease trajectories over 24 weeks for 16 patients enrolled in NS-065 / NCNP-01-201 and 69 patients enrolled in the CINRG DNHS found that patients in the natural history comparison group exhibited declines in time-function tests over the 24-week time frame. In contrast, patients enrolled in NS-065 / NCNP-01-201 showed mean improvements in time-function tests over the same 24-week period. Three of these improvements reached statistical significance: TTRW (weeks 13 and 25); TSTAND (week 25); and 6MWT (week 25). No statistically significant differences were observed between the 40 mg / kg / week and 80 mg / kg / week doses of NS-065 / NCNP-01 (Viltolarsen).

[0145] Figure 4 (a total of five graphs and one table) shows a comparison of the change from baseline in chronofunctional tests over 24 weeks in patients enrolled in NS-065 / NCNP-01-201 (shown as "Viltolarsen" in the solid blue line) and matched patients in the CINRG DNHS (shown as "DNHS" in the dashed red line).

[0146] In the five graphs in Figure 4, "Viltolarsen" is the International Nonproprietary Name (INN) of NS-065 / NCNP-01. In all graphs, changes from baseline were compared between the Viltolarsen-treated group and the CINRG DNHS patient group using a restricted maximum likelihood (REML)-based mixed model for repeated measures (MMRM) analysis.

[0147] (1) Timed Function Test The time-function tests were TTSTAND, TTRW, TTCLIMB, and 6MWT. TSTAND and TTRW were prespecified as separate endpoints and were assessed based on time and a 6-point rating scale. TSTAND and TTRW are also components of the NSAA. Therefore, they were measured once and used as standalone endpoints and also combined as part of the NSAA study. TSTAND and TTRW are further described below in relation to the combined NSAA scales. TTCLIMB was used to assess the time (in seconds) it took patients to climb the four steps. It should be noted that the clinical protocol described above in the "US / Canada Phase 2 Study" erroneously states that the TTCLIMB study was conducted as part of the NSAA.

[0148] The 6MWT is a widely used and accepted test in many diseases, among which the version used in this study was adapted for DMD. The test is considered to be a simple, standardized, low-tech, and cost-effective means of clinically assessing 1) functional motor status, and 2) integrated global response to exercise. To perform the test, two points (cones) were placed 25 meters apart, and patients were asked to walk quickly and safely between the cones for 6 minutes. The total distance (in meters) walked by the patients in the 6 minutes was recorded.Clinical assessors measured the number of steps patients took for the first 50 meters and the total distance (meters) walked in 6 minutes (Craig M. McDonald, MD, Erik K. Henricson, MPH, Jay J. Han, MD, R. Ted Abresch MS, Alina Nicorici, BS, Gary L. Elfring, MS, Leone Atkinson MD, PhD, Allen Reha BS, Samit Hirawat MD, and Langdon L. Miller MD, “The 6-minute Walk Test as a New Outcome Measure in Duchenne Muscular Dystrophy,” Muscle & Nerve, Vol. 41, pp. 500-510, April 2010, Wiley Periodicals, Inc. and Craig M. McDonald, MD, Erik K. Henricson, MPH, R. Ted Abresch, MS, Julaine Florence, PhD, Michelle Eagle, PhD, Eduard Gappmaier, PhD, Allan M. Glanzman, DPT, Robert Spiegel, MD, Jay Barth, MD, Gary Elfring, MS, Allen Reha, MS, and Stuart W. Peltz, PhD, “The 6-minute Walk Test and Other Clinical Endpoints in Duchenne Muscular Dystrophy: Reliability, Concurrent Validity, and Minimal Clinically Important Differences from a Multicenter Study,” Muscle & Nerve, Vol. 48, pp. 357-368, September 2013, Wiley Periodicals, Inc.).

[0149] Quantitative Muscle Testing (QMT) assessment is designed to measure muscle force produced during static contraction and is a well-established method for measuring muscle weakness in neuromuscular diseases. This method used the CINRG Quantitative Muscle System (CQMS). The CQMS includes an audiovisual feedback process that increases suitability in children with DMD. Patients were positioned on an examination table equipped with a back support mechanism, thus eliminating the need for manual back stabilization. After a single practice administration, each patient completed a QMT assessment with scoring (two tests were performed and the higher of the two values ​​was used for data analysis). QMT was performed using a direct computer interface with strain gauges and recording the force as pounds. Test positions and test order were standardized. The following muscle groups were tested bilaterally (Mayhew JE, Florence JM, Mayhew TP, Henricson EK, Leshner RT, McCarter RJ, et al., “Reliable surrogate outcome measures in multicenter clinical trials of Duchenne muscular dystrophy,” Muscle & Nerve, 2007; 35(1):36-42. Epub 2006 / 09 / 14.): Hand grips. Elbow flexors (biceps). ·Elbow extensor (triceps). · Knee flexors (hamstrings). ·Knee extensors (quadriceps).

[0150] For QMT, slight decreases in mean strength were observed for all parameters over the 24-week treatment period, except for the elbow extensor, which showed slight increases (improvements) in strength. No statistically significant changes from baseline at week 25 were observed for any of the parameters.

[0151] Strength and function tests were performed in the following order: TTSTAND, TTRW, TTCLIMB, NSAA, 6MWT, and QMT.

[0152] (2) North Star Ambulatory Assessment (NSAA) The NSAA is a 17-item clinician-rated functional assessment system originally designed for boys with DMD who can walk at least 10 meters (ES Mazzone, S. Messina, G. Vasco, M. Main, M. Eagle, A. D'Amico, L. Doglio, L. Politano, F. Cavallaro, S. Frosini, L. Bello, F. Magri, A. Corlatti, E. Zucchini, B. Brancalion, F. Rossi, M. Ferretti, MG Motta, MR Cecio, A. Berardinelli, P. Alfieri, T. Mongini, A. Pini, G. Astrea, R. Battini, G. Comi, E. Pegoraro, L. Morandi, M. Pane, C. Angelini, C. Bruno, M. Villanova, G. Vita, MA Donati, E. Bertini, and E. Mercuri, “Reliability of the North Star Ambulatory Assessment in a multicentric setting,” Neuromuscular Disorders, Vol. 19, Issue 7, pp. 458-461, Jul 2009, Elsevier BV). This assessment tool evaluates functional activities including standing, rising from the floor, routine steps, hopping, and running. The assessment is based on a 3-point rating scale: 2=ability to perform the test successfully; 1=able to perform the test with modified methods or assistance; and 0=unable to perform the test. Thus, total scores can range from 0 (completely unable to walk) to 34 (no disability) on these assessments. Individual test item scores and total scores were recorded. TSTAND and TTRW were performed as part of the NSAA. The TTSTAND is a routine test performed as a standard clinical examination for DMD patients. The test assesses the time it takes for a patient to stand from lying flat on the floor. The number of seconds needed to perform the test was recorded, as well as a score out of 6 for how well the patient reached the upright position. The TTRW was used to assess the time (in seconds) it took patients to walk / run 10 metres (including a 6-point rating scale for the quality of running / walking).

[0153] US / Canadian Phase 2 Study: Safety Safety data from 16 patients with DMD who received high and low doses of NS-065 / NCNP-01 (Viltolarsen) (40 mg / kg / week or 80 mg / kg / week) did not reveal any major concerns regarding study conduct, data quality, or participant safety. No participants discontinued treatment at the 48-week point. Specifically, there were no treatment-emergent adverse events (TEAEs) that required discontinuation or dose reduction of NS-065 / NCNP-01 (Viltolarsen). All adverse events (AEs) were mild or moderate in severity. EXAMPLES

[0154] Effect of pH on the stability of viltolarsen. (a) pH stability evaluation (1) To investigate the relationship between solution properties and the stability of viltolarsen, the stability of viltolarsen in solutions of various pH values ​​(pH 3, 4, 5, 6, 7, 8, 9, 10, or 11) was evaluated.

[0155] [Test conditions] Drug concentration: Viltolarsen 2 mg / mL Lysis solution: Britton-Robinson buffer (pH 3, 4, 5, 6, 7, 8, 9, 10 or 11) Storage conditions: (1) 121°C (autoclaved) for 10, 30, or 60 minutes; or (2) 4 or 7 days in an incubator at 80°C Endpoints: Appearance (visual confirmation), pH (pH meter), purity test (HPLC method), recovery rate (residual rate) (HPLC method) HPLC conditions: Flow rate: 1.0mL per minute Detector: International spectrophotometer (measurement wavelength: 264 nm) Column: A stainless steel tube having an inner diameter of 4.6 mm and a length of 15 cm was packed with 3.5 μm octadecylsilylated silica gel for liquid chromatography (Waters, X-bridge C18). Column temperature: 60℃ Mobile phase: Dissolve 1.42 g of disodium hydrogen phosphate in approximately 750 mL of water, add an aqueous solution of sodium hydroxide to adjust the pH to 12.0, and then add water to make up to 1000 mL (Solution P). 300 mL of acetonitrile was added to 700 mL of P solution, and 16.12 g of tetrabutylammonium bromide was dissolved in it (mobile phase A). 300 mL of acetonitrile was added to 300 mL of P solution, and 9.67 g of tetrabutylammonium bromide was dissolved in it (mobile phase B). Mobile phase delivery: Mobile phase A / B was changed from (100 vol% / 0 vol%) to (0 vol% / 100 vol%) over 30 minutes. In this example and the following examples, the purity test value is expressed as the percentage of the area of ​​the main peak of Viltolarsen (main peak area percentage (%)) when the total area of ​​all detected peaks including impurities is set to 100.

[0156] [Test Results] The test results are shown in Table 10 and Figure 5. "ST" refers to an aqueous solution of Viltolarsen diluted with purified water at the same drug concentration, which was prepared each time the test was performed (not stored). As a result, Viltolarsen was unstable in solutions in the acidic range, but was relatively stable in neutral to weakly alkaline solutions.

[0157] [Table 10]

[0158] (a) pH-stability evaluation (2) To investigate the stable pH range of viltolarsen in more detail, the stability of viltolarsen in various pH solutions from 6 to 9 was evaluated using potassium phosphate-borax buffer (pH 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, or 9.2).

[0159] [Test conditions] Drug concentration: Viltolarsen 2 mg / mL Dissolution medium: Potassium phosphate-borax buffer (pH 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0 or 9.2) Storage conditions: (1) 121°C (autoclaved) for 10, 30, or 60 minutes; or (2) 1, 4, 7 or 14 days in an incubator at 80°C Endpoints: Appearance (visual confirmation), pH (pH meter), purity test (HPLC method), recovery rate (residual rate) (HPLC method) HPLC conditions: Same as (a) except that the column temperature was 50°C.

[0160] [Test Results] The test results are shown in Table 11 and Figure 6. As a result, viltolarsen was most stable in solutions with a pH of 7 to 7.5.

[0161] [Table 11] EXAMPLES

[0162] Effect of pH modifiers on formulation stability The purpose of this example is to select a pH adjuster for adjusting the pH range of Viltolarsen injection to a stable pH range (pH 7 to 7.5). The stability of 10 mg / mL Viltolarsen solution adjusted to a stable pH by adding various pH adjusters (10 mM KH2PO4, 10 mM Na2HPO4, 10 mM KH2PO4-Na2HPO4, or 100 mM KH2PO4-Na2HPO4) was evaluated.

[0163] [Test conditions] Drug concentration: Viltolarsen 10 mg / mL Drug formulation: See Table 12 below Storage conditions: 121℃ (autoclaved) for 30-60 minutes Endpoints: Appearance (visual confirmation), pH (pH meter), purity test (HPLC method), recovery rate (residual rate) (HPLC method)

[0164] [Table 12]

[0165] [Test Results] The test results are shown in Table 13 and Figure 7. As a result, Viltolarsen was as stable or more stable without a buffer than with a phosphate buffer. In particular, it was more stable than in a high-concentration phosphate buffer (100 mM KH2PO4-Na2HPO4 in this example).

[0166] [Table 13] EXAMPLES

[0167] Relationship between buffer and multimer formation Viltolarsen may form polymers under certain storage conditions, resulting in a decrease in the purity of the monomer. In this example, the formation of polymers was measured when various buffers were added to a 50 mg / mL Viltolarsen drug solution containing 0.9% sodium chloride as an isotonicity agent.

[0168] [Test conditions] Drug concentration: Viltolarsen 50 mg / mL Storage conditions: Up to 5 days in a 60℃ incubator Endpoint: Multimer (HPLC method, SEC column) Analysis conditions: Detector: UV spectrophotometer (measurement wavelength: 260 nm) Column: A stainless steel tube with an inner diameter of 7.8 mm and a length of 30 cm was packed with 7 μm styrene vinyl polymer gel for liquid chromatography, and two such columns were connected in series (TSK gel G3000 PWXL, 7 μm, 7.8 mm × 30 cm, Tosoh). Column temperature: 25°C Mobile phase: 15.6 g of sodium dihydrogen phosphate dihydrate was dissolved in 750 mL of water, and sodium hydroxide solution was added to adjust the pH to 7.3, and then water was added to make up to 1000 mL. 200 mL of acetonitrile was added to 800 mL of this solution. Flow rate: Adjusted so that the retention time of the Viltolarsen monomer was about 21 minutes. Area measurement range: Range up to the Viltolarsen monomer peak

[0169] [Test Results] The test results are shown in Table 14. As a result, the addition of 50 mM phosphate buffer (sodium dihydrogen phosphate dihydrate-disodium hydrogen phosphate: NaH2PO4 2H2O-Na2HPO4) or citrate buffer (sodium citrate trihydrate) increased the production of polymers.

[0170] [Table 14] EXAMPLES

[0171] Solubility study (100mg / mL) We investigated increasing the concentration of the injection solution.

[0172] [Test conditions] Chemical solution: The following two types

[0173] [Table 15] Filtration filter: PVDF (Millex GV, 0.22 μm, 33 mm, Millipore) Endpoints: Appearance (visual confirmation), pH (pH meter), purity test (HPLC method), Recovery rate after filtration (HPLC method)

[0174] [Test Results] The test results are shown in Table 16. When 100 mg / mL viltolarsen injection was prepared, there were no problems with solubility or filtration through a sterile filter, and it became a colorless, clear solution. After storage in a cool place, the solution became viscous, but there was no change in appearance. From the above, it was found that it is possible to prepare a 100 mg / mL injection.

[0175] [Table 16] EXAMPLES

[0176] Solubility study (50mg / mL) The solubility of a 50 mg / mL drug solution was evaluated. A drug solution was prepared and the solubility was measured and the solution was filtered using a sterilizing filter.

[0177] [Test conditions] Chemical solution:

[0178] [Table 17] Filtration filter: PVDF (Millidisc cartridge filter, 0.22 μm, MCGL40S03 / 1pc + MCGL40S03 / 2pc, Merck) Endpoints: Appearance (visual inspection), pH (pH meter), purity test (HPLC method), quantification (HPLC method)

[0179] [Test Results] The test results are shown in Table 18. As a result, the 50 mg / mL solution was a colorless, clear solution, and there was no change in the content before and after filtration. From the above, it was possible to prepare a 50 mg / mL injection solution, and there were no problems with scaling up.

[0180] [Table 18]

[0181] In the following Examples 8 to 10, samples obtained from patients who participated in the clinical trial of Example 2 or patients who participated in the clinical trial of Example 2 were tested. EXAMPLES

[0182] Mass spectrometric quantification of dystrophin protein (Experimental Method) Overview: Biological analysis methods Proteins from the samples were separated by SDS-PAGE electrophoresis, and then enzymatically digested with trypsin in the gel to obtain peptide fragments. The peptide fragments were extracted from the gel pieces and dried. The peptides were redissolved, and dystrophin protein was identified and quantified by HPLC-MS / MS using a reversed-phase column. The range of the calibration curve was 1% to 25% of the amount of dystrophin protein in the normal control, which was taken as 100%, and the concentration was calculated from the peak area ratio using filamin C as the standard protein. The least squares method was used for the regression equation, and the equation y = mx + b (y: peak area ratio, x: % dystrophin) was obtained.

[0183] In-gel digestion The samples to be measured by LC-MS / MS analysis were subjected to SDS-PAGE (SDS: sodium dosidyl sulfate, PAGE: polyacrylamide electrophoresis), proteins were separated by molecular weight, and obtained by in-gel digestion. Each gel consisted of 11 samples in total, including a standard curve consisting of calibrants (0.0%, 1.0%, 3.0%, 10.0%, 25.0% dystrophin), 12.5 μg of protein extracted from human myotube cells cultured with stable isotope-labeled amino acids (SILAC), a blank, and 4 clinical trial samples. The gel had 12 lanes, and the remaining lane was used for a molecular weight marker. The calibrants were prepared by mixing protein extracts from 5 types of non-DMD muscle biopsies and 2 types of DMD muscle biopsies. The DMD muscle biopsies were obtained from Binghamton University and had passed ethical review. Prior to this example, the amount of dystrophin in each muscle biopsy was measured in advance by Western Blot. Seventy serial sections, 10 μm thick, were obtained from muscle biopsies using a cryosectioning apparatus. Muscle sections were transferred to microtubes that had been chilled on dry ice. Proteins were extracted from muscle sections using RIPA buffer supplemented with protease and phosphatase inhibitors from Thermo Scientific. Protein concentrations of the extracts were quantified using a BCA protein assay kit (Pierce). Samples were adjusted to contain 50 μg of protein and 12.5 μg of SILAC was added to each sample for electrophoresis. SILAC extract was added to calibrators and clinical samples as an internal standard for determining % dystrophin. NuPAGE 3-8% Tris-Acetate gels were electrophoresed at 150 V for 75 min. Gel electrophoresis was performed in duplicate using two gels (gel A and gel B) for the same sample. After electrophoresis, the gel was fixed in methanol:water:acetic acid (50:45:5) for 30 minutes, then exchanged with water and rehydrated twice. Coomassie blue staining was performed for 1 hour. The gel was destained overnight at 4°C. The gel containing dystrophin protein with molecular weight markers ranging from 460 kDa to 268 kDa was excised and washed twice with water:acetonitrile (50:50).The peptide fragments were obtained by in-gel digestion using trypsin (Gold mass spectrometry grade, Promega Corporation) and dried by vacuum centrifugation. The dystrophin peptide fragments were stored at -80°C and used for analysis by Q Exactive Nano-LC-MS / MS.

[0184] Test sample Sixteen patients participated in the clinical trial, and muscle biopsies were obtained from each patient before and after administration. 64 samples were analyzed from 32 samples due to duplicates. In addition, eight samples, which were duplicates of four samples, were reanalyzed, so a total of 72 samples were analyzed.

[0185] Analysis by LC-MS / MS The obtained peptide fragments were analyzed by liquid chromatography-mass spectrometry (LC-MS / MS) using a combination of a high-performance liquid chromatography system Dionex Ultimate 3000 RSLCnano (ThermoFisher Scientific) and a mass spectrometer Q Exactive Plus (HRMS: High Resolution Mass Spectrometer) (ThermoFisher Scientific). The dried peptide fragments were redissolved in 2% acetonitrile (ACN) + 0.1% trifluoroacetic acid (TFA). A 5 μL Dinoex nanoViper sample loop (ThermoFisher Scientific) was used for sample introduction into the LC-MS / MS.

[0186] Liquid chromatography was performed under the following conditions. Analytical column: Reversed phase column Acclaim Pepmap RSLC C18 15cm x 75 μm, particle size 3 μm, EASY SPRAY (Thermo Fisher) Analytical column temperature: 50℃ Mobile phase A: 1% formic acid (HCOOH), Mobile phase B: 0.1% formic acid ACN Flow rate: 0.500 μL / min (NC) Sample injection mode: Partial loop (loop size 5 μL) Sample injection volume: 1.00 - 4.00 μL Autosampler temperature: 10℃ Run Time: 40.00 minutes

[0187] [Table 19]

[0188] The mass spectrometer was used under the following conditions. Ion source: Thermo Fisher EASY-Spray Ion mode: Positive ion Scanning: Parallel reaction monitoring Chromium peak width (full width at half maximum): 10 seconds Minimum total cycle time: 40 minutes Resolution: 17,500 Automatic Gain Control target: 1e5 Maximum sample injection time: 50 ms Quadrupole mass detector separation width: 1.0 m / z units Spectrum Data: Profile Mass tolerance: 10 ppm Typical Tunable Parameters (Dystrophin Tune File) Spray voltage: 1.8 kV Capillary Temperature: 275℃ S-Lens RF-Level:70

[0189] [Table 20]

[0190] [Table 21]

[0191] [Table 22]

[0192] Data was collected from the chromatography using Thermo Scientific's LC Quan version 3.0. The mass tolerance was 20 ppm, and the integration algorithm was ICIS. When the peak area of ​​dystrophin in the 1% calibrant or other calibrants was around 10,000 or less, the following was noted. Compared with the 0% calibrant, it was confirmed that the peak area ratio of the peptide and the labeled peptide obtained for both dystrophin and filamin C was a reliable value and did not affect the % dystrophin. The peak areas of dystrophin and filamin C were calculated by summing the peak areas corresponding to the product ions. The peak area of ​​dystrophin was obtained from one peptide fragment of dystrophin (DYST2 amino acid sequence: IFLTEQPLEGLEK (SEQ ID NO: 4)). The peak area of ​​filamin C was the average value of two peptide fragments of filamin C (FILC1 amino acid sequence: VAVGQEQAFSVNTR (SEQ ID NO: 6), FILC2 amino acid sequence: SPFVVNVAPPLDLSK (SEQ ID NO: 8)).

[0193] [Table 23]

[0194] The dystrophin protein levels (peak area ratio of dystrophin to filamin C) in the calibrators and each clinical sample were calculated using the following formula. Because dystrophin was also detected in the 0% calibrator, the dystrophin protein level values ​​of each calibrator were subtracted from the dystrophin protein level values ​​of the 0% calibrator to correct the levels. Using an Excel template, a regression line was obtained between the % dystrophin and dystrophin protein level values ​​from the calibrators for each gel, and the % dystrophin of the clinical samples was obtained from the dystrophin protein level values ​​of the clinical samples.

number

[0195] [Table 24]

[0196] (result) The % dystrophin of each analyzed sample was determined based on the pass / fail criteria specified in advance. Of the 72 samples measured, 60 samples met the criteria. The measurement results are shown in Tables 25 and 26. Although the test was performed using duplicate samples for each specimen, for the four specimens obtained before and after administration from two patients in the 40 mg / kg administration group (patients E and F in Table 25), one sample (gel B) did not meet the criteria, so only one measurement value was obtained from one sample (gel A). That is, in the 40 mg / kg administration group, 14 out of 16 samples from 8 specimens before administration could be measured. One sample showed 1%, and 11 samples were below the limit of quantification. In addition, 14 out of 16 samples from 8 specimens at 25 weeks could be measured. One specimen was below the limit of quantification in both measurements, and 1% or more of dystrophin was detected. In the 80 mg / kg group, all 16 samples from 8 specimens before treatment were below the limit of quantification. At 25 weeks, all 16 samples from 8 specimens had dystrophin levels above the limit of quantification, with an average of 4.2%. These results confirmed that administration of 40 mg / kg and 80 mg / kg of viltolarsen restored dystrophin protein expression.

[0197] [Table 25]

[0198] [Table 26] EXAMPLES

[0199] Motor function test (at 13 and 25 weeks (12 and 24 weeks after the first administration)) (Experimental Method) The motor function assessments of the drug group were compared with those of the natural history group, which was selected based on baseline data from a study called the Duchenne natural history study (CINRG DNHS), conducted by the Cooperative International Neuromuscular Research Group (CINRG), a US clinical trial network for muscular dystrophy. The CINRG DNHS is a longitudinal natural history study of 440 men with DMD, with data collected from 2006 to 2016. Patients were scheduled to visit the hospital at baseline, four times in the first year, twice in the second year, and once a year for up to 10 years. At each visit, timed function tests, muscle strength tests, questionnaire-based function tests, pulmonary function tests, and quality of life assessments were performed. 201 studies were conducted by CINRG-affiliated centers, and standard operating procedures (SOPs) and clinical assessor training procedures were consistent between the two studies.

[0200] Patients who met the following criteria, including the main enrollment criteria for Study 201, such as age, steroid use status, and region, were selected from the CINRG DNHS as controls for this study. Have at least 12 months of functional test data (baseline data on time to stand (TTSTAND), time to climb 4 steps (TTCLIMB), and time to walk / run 10 m (TTRW) are required). Age 4 to <10 years at baseline · North America (USA or Canada) - Corticosteroids have been administered for at least 3 months and have been continued throughout the 12-24 month observation period. Not simultaneously enrolled in clinical trials of other exon skipping drugs. Meet the genetic eligibility criteria listed below. (Selection criteria): Patients with genetic test results Patients with duplication mutations Patients with nonsense or frameshift mutations (Exclusion criteria): Patients with mutations between the promoter and exon 8 (excluded due to reports of slow progression of the disease (1) Hum Mutat. 2018; 39: 1193-1202 and (2) Hum Mutat. 2008; 29(5): 728-37) Patients suitable for exon 44 skipping therapy (excluded due to reports of slow disease progression (1)) Patients with in-frame mutations

[0201] As a result, 65 male DMD patients met the above criteria, of which 9 were DMD patients suitable for treatment with exon 53 skipping (exon 53 skipping group) and 56 were DMD patients not suitable for treatment with exon 53 skipping (non-exon 53 skipping group).

[0202] [Table 27]

[0203] (result) Changes in functional tests (6-minute walk test (6MWT), time to stand (TTSTAND) speed, time to climb 4 steps (TTCLIMB) speed, and 10-meter run / walk time (TTRW) speed) and North Star Ambulation Assessment (NSAA) from pre-treatment or baseline at 13 and 25 weeks were compared in 16 subjects treated with viltolarsen (viltolarsen group) and 65 subjects in the CINRG DNHS natural history group (DNHS group). In the analysis method used in this example, the "pre-treatment value" or baseline was used as a covariate, which is a background factor that affects the results, and the data at 13 and 25 weeks were used as repeated measures for a specific subject, and MMRM analysis was performed. As a result, the 6-minute walking distance and 10-meter running / walking time speed were significantly improved in the Viltolarsen group in this example. In addition, all other motor function tests were improved in the drug group compared to the natural history.

[0204] Figure 8 is a graph showing the change from baseline in the results of each motor function test in the Viltolarsen group and the CINRG natural history control group (DNHS) at 13 weeks of administration (12 weeks after the first administration) and 25 weeks of administration (24 weeks after the first administration). The changes were calculated using least squares means of the changes from baseline to 13 weeks and 25 weeks, error bars are standard errors, and P values ​​were calculated using MMRM.

[0205] The viltolarsen administration groups and sample sizes at each DNHS time point were as follows: [Table 28]

[0206] [Table 29] EXAMPLES

[0207] Motor function test (up to 85 weeks (84 weeks after first administration)) (Experimental Method) Functional tests (6-minute walk test (6MWT), time to stand (TTSTAND), time to climb 4 steps (TTCLIMB), 10-meter run / walk time (TTRW)) and North Star Ambulation Assessment (NSAA) were measured 1 week before the first dose and at 12-week intervals (13, 25, 37, 49, 61, 73, 85 weeks) from the first dose. The 201 study was conducted by a facility affiliated with CINRG, and the motor function tests were performed in accordance with the standard operating procedures (SOPs) and clinical assessor training procedures used in the CINRG DNHS. Some items could not be performed due to the fact that the subjects were children and their interest in the tests was not sustained.

[0208] (result) The results are shown in Figures 9 to 16. In the North Star Ambulation Assessment, scores were maintained or improved in many patients aged 5 years or older in the Viltolarsen group. According to a paper that studied the change in NSAA score after 1 and 2 years using patient entry criteria similar to those of clinical trials based on natural history data from Italy and the UK, the average change in exon 53 skipping treatment patients was -4.1 points per year (J Neurol Neurosurg Psychicary 87, 149-55, 2016). The change at 48 weeks in patients in the Viltolarsen group who met the entry criteria in the paper was +1.3 points. In a paper reporting the results of DHNS (Muscle Nerve 48, 55-67, 2013), 20% of DMD patients aged 7 to 9 years lost the ability to stand up, but no patients in the Viltolarsen group met this criteria. Ten percent of DMD patients aged 7 to 9 years lose the ability to walk independently, but none of the Viltolarsen-treated patients were affected. Speed ​​decreases with age, but overall speed increases in the Viltolarsen-treated group. Ten percent of DMD patients aged 7 to 9 years lose the ability to walk independently, but none of the NSP patients were affected. Speed ​​in the 10-meter run / walk time also decreases with age, but overall speed increases in the Viltolarsen-treated group. The correlation between the change in dystrophin expression from baseline in WB quantification and the change in speed from baseline in the stand-up time test, the 4-step stair climbing test, and the 10-meter walk / run test over 48 weeks was calculated using Excel, and linear regression equations were calculated. There was a significant correlation between dystrophin expression and speed change in the stand-up time test and the 10-meter run / walk test (P < 0.05), suggesting that the increase in dystrophin increases the speed change of motor function. Industrial Applicability

[0209] The present invention provides a pharmaceutical composition for treating Duchenne muscular dystrophy, which has a stable composition of NS-065 / NCNP-01 (Viltolarsen). In addition, the pharmaceutical composition containing NS-065 / NCNP-01 (Viltolarsen) is provided with a dosage regimen that effectively treats DMD and is safe for human patients. The pharmaceutical composition can effectively alleviate symptoms of Duchenne muscular dystrophy with low side effects.

Claims

1. 1. A pharmaceutical composition for treating a human patient with Duchenne muscular dystrophy (DMD), comprising: (i) an antisense oligomer, a pharma- ceutically acceptable salt or hydrate thereof, in a concentration of 50 mg / ml; and (ii) sodium chloride in a concentration of 8 mg / ml to 10 mg / ml; the antisense oligomer is Viltolarsen and comprises a base sequence complementary to a sequence consisting of nucleotides 36 to 56 from the 5' end of exon 53 of the human dystrophin gene; the pharmaceutical composition is an aqueous solution having a pH between 7.0 and 7.5; The pharmaceutical composition does not contain a phosphate buffer.

2. The pharmaceutical composition of claim 1 , further comprising no citrate buffer.

3. The pharmaceutical composition of claim 2 which does not contain a buffer.

4. 10. The pharmaceutical composition of claim 1, further comprising at least one component selected from the group consisting of an isotonicity agent, a pH adjuster, and a solvent.

5. 5. The pharmaceutical composition of claim 4, wherein the isotonicity agent is at least one selected from the group consisting of sodium chloride, potassium chloride, glucose, fructose, maltose, sucrose, lactose, mannitol, sorbitol, xylitol, trehalose and glycerin.

6. The pharmaceutical composition according to claim 4, wherein the pH adjuster is at least one selected from the group consisting of hydrochloric acid, sodium hydroxide, citric acid, lactic acid, and monoethanolamine.

7. The pharmaceutical composition of claim 4, wherein the solvent is water.

Citation Information

Patent Citations

  • Antisense nucleic acids

    JP2014054250A

  • oligomers

    US20100168212A1

  • ENA NUCLEIC ACID DRUGS MODIFYING SPLICING IN mRNA PRECURSOR

    WO2004048570A1

  • Antisense oligonucleotides for inducing exon skipping and methods of use thereof

    WO2006000057A1

  • Multiple EXON skipping compositions for dmd

    WO2010048586A1